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Abstract
Most in vivo models of ischaemic stroke target the middle cerebral artery and a spectrum of stroke severities, from mild
to substantial, can be achieved. This review describes opportunities to improve the in vivo modelling of ischaemic stroke
and animal welfare. It provides a number of recommendations to minimise the level of severity in the most common
rodent models of middle cerebral artery occlusion, while sustaining or improving the scientific outcomes. The recom-
mendations cover basic requirements pre-surgery, selecting the most appropriate anaesthetic and analgesic regimen, as
well as intraoperative and post-operative care. The aim is to provide support for researchers and animal care staff to
refine their procedures and practices, and implement small incremental changes to improve the welfare of the animals
used and to answer the scientific question under investigation. All recommendations are recapitulated in a summary
poster (see supplementary information).
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1 Introduction
1.1 Background
Strokes are caused when there is an interruption in the
blood supply to the brain, by either leaking (haemor-
rhagic stroke) or more commonly blocking (ischaemic
stroke) of blood vessels supplying brain tissue. Despite
signiﬁcant reductions in stroke incidence and mortality
in the last 25 years, over 100,000 people have a stroke in
the UK every year which is fatal in 12% of patients in
the ﬁrst 30 days and represents a major cause of mor-
bidity, with almost two-thirds of stroke survivors leav-
ing hospital with a disability.1 Available treatments for
ischaemic stroke are largely limited to mechanical or
pharmacological (thrombolysis) strategies to re-open
the blocked blood vessel and are suitable for only a
small minority of patients. Other important strategies
include preventing recurrent stroke, maximising the
rehabilitation achieved and preventing or treating com-
plications. There are at present no treatments, other
than restoring cerebral blood ﬂow (CBF), which pro-
tect the remaining brain substance and structures from
the consequences of stroke (neuroprotection) or assist
in repairing the brain (neuroplasticity).
Research using various approaches including animal
models of stroke has led to a sophisticated understand-
ing of the eﬀects of ischaemia in the mammalian brain,
and as far as we can tell, the majority of these patho-
logical processes are largely shared across species
including between rodents and humans. This identiﬁes
rodent models of ischaemic stroke (see O’Neill and
Clemens2,3 and Howells et al.4 for overviews) as
useful tools in the development and testing of novel
treatments.
Many hundreds of compounds have been tested in
experimental models of stroke5 and many of these
appear to improve outcome. However, of almost 100
interventions which improved outcome in animal
stroke models and which were tested in clinical trials,
only one (re-opening the blocked blood vessel with
recombinant tissue plasminogen activator (rtPA))
improved outcome in humans.5
In some cases the reasons for this failure of transla-
tion are readily apparent: gavestinel (an antagonist of
glycine at the N-methyl-D-aspartic acid (NMDA)
receptor) improves outcome in animals, but has very
low penetration to the human brain and cerebrospinal
ﬂuid (CSF); tirilazad was eﬀective in animals when
given a median of 10min after stroke onset, but not
in human clinical trials when the delay to treatment
was more than 3 h for three quarters of the patients
included in the study. For others, systematic review of
the supporting animal literature suggests that the
apparent eﬃcacy observed in those studies may have
been due to suboptimal experimental design.6 For
instance, studies which do not report strategies such
as randomisation or blinding to reduce the risk of
bias tend to give inﬂated estimates of drug eﬀect; and
in the past only a minority of stroke studies reported
using any such strategies. Finally, it may be that the
animal literature apparently supporting eﬃcacy repre-
sents only a subset of the experiments performed, the
others being resolutely neutral or negative, but not pub-
lished. This problem of publication bias has been esti-
mated to lead to an overstatement of eﬃcacy of around
30%7; and publication bias magniﬁes the eﬀects of inad-
equate sample size (and therefore statistical power),
where it is only the studies which (by chance) show
extreme eﬀects which reach the published literature.
These problems are by no means limited to the mod-
elling of stroke, but because they were ﬁrst identiﬁed
here, the in vivo stroke community has been well placed
to take the lead in addressing them. This was manifest
in the Stroke Therapy Academic Industry Roundtable
(STAIR) criteria,8,9 model-speciﬁc good laboratory
practice guidelines10 and changed editorial policies at
both the Journal of Cerebral Blood Flow and
Metabolism and Stroke. In a recent assessment of
reporting standards for all in vivo research from lead-
ing UK institutions, only one publication met all four
reporting criteria, and this publication described in vivo
stroke research.11
Despite this progress, there are opportunities to fur-
ther improve the in vivo modelling of ischaemic stroke.
This will not only increase the reliability and economic
productivity of research but will also improve the skill
base of the scientiﬁc workforce and, by maximising the
value of the information gained from animal research,
will provide a ﬁrmer ethical basis for such work. Against
this background we consider here issues of animal wel-
fare, and provide a number of recommendations for
strategies to minimise pain and distress in these
models, and thereby also improve scientiﬁc outcomes.
1.2 Working group
The National Centre for the Replacement, Reﬁnement
and Reduction of Animals in Research (NC3Rs) is a
2 Journal of Cerebral Blood Flow & Metabolism
scientiﬁc organisation established by the United
Kingdom (UK) Government in 2004 to lead the discov-
ery and application of new technologies and
approaches to replace, reduce and reﬁne the use of ani-
mals for scientiﬁc purposes. In 2014 the NC3Rs con-
vened an expert Working Group with the following
terms of reference:
1. To review the most commonly used rodent (mouse
and rat) models of stroke.
2. To identify the animal welfare issues.
3. To recommend opportunities for reﬁnement.
4. To publish the deliberations of the Working
Group and promote its recommendations within
the international stroke research community.
The overall aim was to provide recommendations
which might reduce the level of severity experienced
by animals in the most common models of middle cere-
bral artery (MCA) occlusion whilst at the same time
sustaining or increasing the value of the science. The
Working Group consisted of UK experts from aca-
demia, the pharmaceutical industry and the UK
Home Oﬃce (the government body with responsibility
for animal research). In addition, several members of
the group, identiﬁed in the author list, were participants
in the Framework 7 Multi-PART project (http://
www.dcn.ed.ac.uk/multipart/), which aims to overcome
the problem of poor translation of preclinical stroke
research by providing a platform for international,
multi-centre preclinical trials to test new therapies,
thus applying the same standards and methodology
used in clinical research. The information and recom-
mendations of the Working Group have drawn in part
on the standard operating procedures proposed by the
Multi-PART team. In addition, some of the authors
participated in a workshop to exchange best practice
and identify reﬁnements for speciﬁc models.
1.3 Considerations of the choice of model
The majority of rodent ischaemic stroke models target
the MCA, with either transient or permanent occlusion.
The main methods of MCA occlusion (MCAO) are: (1)
mechanical – e.g. blocking the origin of the MCA intra-
luminally with a ﬁlament, using clips and/or sutures to
tie oﬀ the artery or applying compression to stop the
ﬂow through the artery; (2) electrocoagulation – coa-
gulating the blood and destroying the structure of the
artery using ﬁne diathermy forceps; (3) pharmaco-
logical – e.g. applying vasoconstrictor substances such
as endothelin-1 directly onto the artery or injecting it
into neighbouring tissue to induce prolonged, local
ischaemia; (4) thrombo/embolic – introducing a pre-
formed blood clot to block the MCA, or its distal
branches, inducing local thrombosis with thrombin
injections or a combination of Rose Bengal and a
laser to form the blood clot.4
While these four main methods of inducing stroke
are those considered in this paper, modiﬁcations and
reﬁnements of these models extend the range even fur-
ther. For example, subcortical structures can be spared
and a pure cortical infarct produced by occluding a
more distal portion of the MCA or its branches
(methods 1, 2 & 4); severity of ischaemia can be
increased by simultaneous uni- or bilateral common
carotid artery (CCA) occlusion or controlled hypoten-
sion (methods 1, 2, 3 & 4). Duration of ischaemia can
be controlled (method 1) and severity/duration inﬂu-
enced by adjusting the concentration or volume of
endothelin-1 (method 3) or the characteristics of the
laser in the Rose Bengal model (method 4).
Therefore, a spectrum of stroke severities, from mild
to substantial, can be achieved using the various
models.
Recommendations on which models are most appro-
priate to use have been the subject of recent extensive
reviews12,13 and are not covered here. Similarly, good
practice in both experimental design10 and reporting14
is also outside the remit of this paper.
As a guiding principle when designing stroke studies,
the model used should deliver the minimum severity
and duration of ischaemic insult required to answer
the scientiﬁc question under investigation or the
hypothesis being tested. In addition, there are two
aspects of stroke severity to consider: that arising in
the course of inducing the model itself, and the severity
of the individual animal outcome. In general the sever-
ity and duration of the ischaemic insult are adjusted to
achieve a measureable and reproducible primary out-
come measure. As is the case in stroke patients, how-
ever, there is often a large heterogeneity in outcome
including morbidity and mortality within a group of
animals exposed to a standard ischaemic insult.
Outcome data are more variable in models of transient
MCA occlusion than in permanent occlusion as transi-
ent models can cause vascular endothelial damage and
secondary reperfusion events may add to the variabil-
ity. The aim should be to reduce unwanted variability
as much as possible to improve signal to noise ratio and
increase the power of the experiments. Factors such as
sex, strain, age and environment also aﬀect the out-
come measure which implies that modiﬁcation of the
environment to improve welfare will have an impact on
the outcome, particularly on the extent of survival and
recovery, as described below.
The structure of the present paper is organised as a
timeline, and diﬀerent sections follow the order these
things would be encountered during the course of the
experiment, from acclimatisation of the animals before
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surgery and choice of anaesthetic regimen through to
the surgery itself and post-operative care. These consid-
erations apply to all rodent ischaemic stroke models,
whereas the last section covers reﬁnements for speciﬁc
models. The recommendations are highlighted in bold
at the end of each section. They are also recapitulated
in a summary poster, which also includes the humane
endpoints and the traﬃc light system to monitor the
animals after stroke (see supplementary information;
the poster would be best printed oﬀ in size A3).
2 Basic requirements pre- and post-stroke
2.1 Acclimatisation pre-stroke
Animals should be acclimatised to new facilities for at
least seven days prior to experimental work commen-
cing and visual inspection of animals to check baseline
normal health status should be undertaken over this
time. Assessing the behaviour and appearance of the
animal (e.g. grooming and coat condition) as well as
body weight not only allows a check of its wellbeing,
but also allows any deviation from normal to be recog-
nised.15 Animals should be weighed daily, for at least
three days before the surgery, as this allows a normal
growth curve to be constructed. This enables any fall in
weight after the procedure and the recovery of weight
to be assessed appropriately.
There is evidence that rodent behaviour, physiology
and sleep patterns are aﬀected by transport.16–18
Physiologically, a number of factors in rodents are
aﬀected, even by routine in-house transport, and can
lead to increased levels of plasma corticosterone,19
decreased immune activity19 and decreased body
weight despite continued access to food and water.20
These eﬀects can take two to four days to normal-
ise.21,22 However, normalisation of behaviour takes
even longer. Rearing, climbing, grooming, feeding
and sexual behaviours of mice change signiﬁcantly
immediately after transportation and take more than
four days to normalise.23 Of note is that transport
between continents (as can be the case with transgenic
mice) may induce an extended light/dark time which
causes circadian rhythm to take more than two weeks
to resynchronise.24 In addition, other environmental
disturbances including husbandry, common experimen-
tal procedures such as handling, injections and even
noise/vibrations due to building/infrastructure work
can alter physiology (increased heart rate and mean
arterial blood pressure) and behaviour (for review
Turner et al.25). It is important that there is stability
in the day-to-day inﬂuences on the animals so that vari-
ability is reduced.
Many species of animals live in hierarchies that
involve dominance and submission. Re-housing
animals in new groups may be a stressful experience if
animals are not compatible. It may disrupt social rela-
tionships, cause aggression and should be avoided
unless absolutely essential.26,27 Accordingly, it is recom-
mended that research groups avoid mixing their ani-
mals when they arrive in the unit and animals should
keep the same cage mates throughout the experiment
and should only be randomised to treatment.
Before the experimental procedures start, rodents
should be acclimatised to handling by the same experi-
menter; this can be done daily during the acclimatisa-
tion period. Evidence shows that regular handling
before behavioural testing has an anxiolytic eﬀect in
both rats28 and mice.29 Handling methods such as cup-
ping mice with open hands or using tunnels are prefer-
able to the traditional approach of picking it up by the
tail, which has been shown to be aversive and to induce
high levels of anxiety in several strains of mice.29,30 For
rats, there are no data on tunnels and cupping is not
possible, but rats should be handled by grasping
around the shoulders, not by the tail. Reducing anxiety
of handling will ensure that the stress response does not
confound the scientiﬁc outcome.
1. Rodents ordered from an outside supplier should
be delivered at least seven days before the proced-
ure to allow acclimatisation to the new
environment.
2. Animals should be acclimatised in harmonious
groups before the start of the experiment. Re-hous-
ing animals in new groups should be avoided.
3. Animals should be acclimatised to handling and
should not be handled by the tail. Tunnel and cup
handling should be used for mice; rats should be
handled by grasping around the shoulders.
4. Animals should be weighed daily for at least three
days before surgery.
2.2 Cage enrichment
The Guide for the Care and Use of Laboratory
Animals31 has deﬁned environmental enrichment as
the provision of structures and/or resources that
improve sensory, motor and psychological wellbeing
of the animal through physical exercise, manipulative
activities and cognitive challenges according to species-
speciﬁc behaviours. The provision of environmental
enrichment is a basic rodent housing and husbandry
requirement to improve overall wellbeing32 (https://
www.nc3rs.org.uk/our-resources/housing-and-husban-
dry/rodents).
As described below, many research groups have now
shown the beneﬁts of ‘enriched environments’ relative
to ‘standard housing’ in both naı¨ve and lesioned
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laboratory animals. However, it is important to remem-
ber that ‘enriched environments’ always fall short of the
natural environment that animals experience in the wild
(e.g. free access to mates, unrestricted three-dimen-
sional complex space to roam, hunting for food
rather than passive ‘chow’). We must recognise that
laboratory animals always live in impoverished envir-
onments relative to animals living in the wild. Thus
any conclusion such as ‘environmental enrichment
increases neurogenesis’ might arguably be better
phrased as ‘standard (impoverished) housing causes
a deﬁcit in neurogenesis’. Environmental enrichment
can be considered as a form of reﬁnement based on
the animals’ needs that improves wellbeing. Therefore
it is recommended that the impact on scientiﬁc
method, outcome and statistical power are evaluated
to ensure the animal model remains intact and to
ensure valid conclusions can be drawn.33
Environmental enrichment in laboratory rodents has
the potential to increase variability in the data.34
However it does not increase the risk of obtaining
conﬂicting data in replicate studies.35 In addition,
the level of enrichment must be considered carefully
given mounting evidence for neurorestorative eﬀects of
‘super-enrichment’ as described below.
In Europe, minimum requirements for the level of
enrichment for standard housing conditions are set by
the EU Directive 2010/63,27 which stipulates that ani-
mals should be provided with ‘space of suﬃcient com-
plexity to allow expression of a wide range of normal
behaviour’. Minimum cage sizes are prescribed for each
species depending on the weight of the animals. For
example, 35 g mice require a minimum enclosure size
and height of 330 cm2 and 12 cm, respectively, with at
least 100 cm2 of ﬂoor area per mouse, while 350 g rats
require a minimum enclosure size and height of 800 cm2
and 18 cm (note that this height is not suﬃcient for
adult rats to rear up; in the UK, the minimum height
is 20 cm36), respectively, with at least 350 cm2 of ﬂoor
area per rat.27 As well as cage substrate, bedding, nest-
ing material and refuges are considered essential for
laboratory rodents and should only be withheld for
veterinary or welfare reasons.37 It is important that
cages contain suﬃcient nesting materials prior to and
after stroke. Laboratory mice are typically housed well
below their lower critical temperature, which is around
30C.38 Deep, thick nests can help control hypothermia
and allow thermoregulation, thus reducing the impact
that thermal stress could have on the scientiﬁc out-
come.38 It is important to provide plenty of nesting
materials at least one day before surgery so that the
animals can assemble their nests as they are likely to
do this less well after stroke. However, the bedding
must be clean after surgery and it should be renewed
if soiled so animals with wounds are not lying on soiled
bedding. Some research groups provide animals with
cages containing plastic housing and opportunities for
exercise. For example, the company Bio-Serv (https://
www.bio-serv.com) sells ‘Igloos’ that mice nest in.
These Igloos may be purchased with a simple wheel
(an oﬀ-horizontal spinning disk) that mice spend a
great deal of time running upon. These are autoclavable
and relatively inexpensive. Chew bars (e.g. aspen sticks)
should be placed into the cages of animals; this
allows expression of normal gnawing behaviour. It
may also help prevent incisor tooth overgrowth,
which is a particular concern in old animals or animals
on a soft diet.
2.2.1 Super-enriched environments. A higher level of
enrichment has been termed ‘super-enriched’ and pro-
vides more complex, multisensory stimulation through
use of, for example, larger multilevel cages, access to
novel and varied toys and equipment for voluntary
exercise (ladders, running wheels), music, odours and
hidden treats.39 Whilst evidence exists for lack of eﬀects
of super-enriched environments on clinical pathology
and cardiovascular parameters,40 it should be noted
that using super-enriched environments, over and
above standard cage enrichment, has been shown by
a meta-analysis of rodent studies to improve functional
outcome in models of stroke.41 Using these sorts of
super-enriched environments should therefore be care-
fully considered, not only as an improvement in animal
welfare, but also because of possible enhancement of
the eﬀects of neurorestorative strategies (for reviews see
Mering and Jolkkonen39 and Nithianantharajah and
Hannan).42 The eﬀects of super-enriched environments
can be dependent on the quantity of environmental
enrichment,43 they may possibly be independent of
infarct size41 and they may possibly involve lesion-
induced increases in cell proliferation in the subventri-
cular zone.44 In addition, if a key goal of the study is to
evaluate functional recovery (behavioural read-outs)
these enrichments may also alter the baseline rate of
recovery post-stroke. Therefore additional enrichment
should be considered carefully45 and it is important that
the quantity and constituents of environmental enrich-
ment are clearly speciﬁed when reporting studies in the
literature.
2.2.2 Special issues relating to animal models of
stroke. Animal models of stroke often deliberately aim
to model co-morbidities found in stroke patients,
including sedentary lifestyles, high fat diets, obesity
and diabetes. Accordingly, stroke researchers may
assert that there may be some face validity in restricting
aspects of cage enrichment. For example, it may be
counter-productive to provide mice with ad libitum
access to running wheels before or after stroke unless
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lean animals and active rehabilitation are desired. Such
decisions should be overt and reported accordingly.
5. Cage substrate, nesting material and shelter are
basic welfare needs for rodents and should be pro-
vided. Tunnels, wheels and chewing sticks are
simple, cost-eﬀective ways to improve enrichment.
6. Additional ‘super-enrichment’ should be considered
carefully, as it may have neurorestorative eﬀects.
Enrichment should be reported in publications
speciﬁcally.
2.3 Bedding material post-surgery
Following surgery, the bedding material must be
chosen so as to avoid complications with feeding and
drinking and not interfere with wound healing. In prac-
tice, there are a number of possibilities, none of which
are perfect or obviate the need for close monitoring.
Several researchers avoid the use of standard cage sub-
strate/bedding as sawdust or wood chippings/shavings
can get caught in the airway of rodents, and long
strands of paper (that resemble those produced by a
shredder of conﬁdential documents) are not recom-
mended as limbs of animals with impaired mobility or
sensation can get caught in the strands. Others prefer to
use absorbent, disposable tray liners or infant bed mats
such as those made by the nappy (diaper) company,
Huggies. These ‘DryNites’ come with adhesive strips
that can be folded to stick onto the ﬂoor of a rat
cage. Some groups place these into the cage the day
before surgery to enable acclimatisation by the animals,
although rodents may shred the liners. Liners allow
monitoring of normal body function and can indicate
if the animals are urinating and defecating. Other
groups prefer the non-ﬁbrous, dust-free pelleted paper
product, 3Rs LAB bedding (http://3rsbedding.com)
which has the advantage of being warm, suitable for
nesting by both rats and mice and requiring infrequent
changes because of its high absorbency. The choice of
product should be made in consultation with the local
vet or animal care staﬀ.
7. In consultation with the veterinary and animal care
staﬀ, consideration should be given to the bedding
materials and any new material should be introduced
prior to surgery to acclimatise the animals.
2.4 Social housing post-stroke
Social grouping is an important component of environ-
mental enrichment by allowing species-typical charac-
teristics such as ﬁghting, playing or sleeping together.46
Animals deprived of the possibility to perform species-
speciﬁc behaviour may show behavioural disorders
or other indicators of chronic stress, including patho-
logical changes. As outlined by the EU Directive 2010/
63 and in section 2.1 ‘Acclimatisation pre-stroke’, we
recommend housing animals as soon as is possible in
the same groups after stroke as they were housed in
before stroke.
Ample evidence shows that recovery from surgery is
improved in mice housed in groups.47 Social isolation
following stroke increases infarct volumes and
decreases brain-derived neurotrophic factor (BDNF)
levels in mice48 and alters the neuroinﬂammatory
response to stroke.49 The protective eﬀects of social
housing after stroke do not appear to be mediated by
passive transfer of body heat but physical contact does
appear to be necessary.49 Concern that cage mates will
remove sutures from each other’s surgical wound is
rarely a signiﬁcant issue, provided wounds are closed
competently. Use of appropriate gauge and type of
suture material, and use of a subcuticular closure tech-
nique can eliminate these concerns. Tissue glue can also
be used in addition to a subcuticular closure.
Animals with small strokes (e.g. small subcortical
infarcts) can be group-housed immediately on recovery
from general anaesthesia but for larger strokes, where
the animals’ behaviours are signiﬁcantly aﬀected, it
may be advisable to house individually in the immedi-
ate post-surgical period to provide additional care, and
allow some degree of recovery and wound healing
before group-housing. Even with a delay of as much
as 72 h post-stroke, pair housing still leads to enhanced
functional recovery.50
While social housing of mice with a healthy (non-
stroke) partner immediately after stroke reduces mor-
tality compared to housing with a stroke partner,50
there are implications for long-term social housing,
and careful experimental design will be required
depending on the nature of the partner animals which
may be either sham-operated (but non-stroke) or naive
(non-operated). If the experiment involves sham-oper-
ated and stroke groups, co-housing the animals is both
a welfare beneﬁt and good scientiﬁc practice. This
should be built into the randomisation protocol to
ensure that each cage will contain sham-operated and
stroke animals.51 Similarly, to rule out cage eﬀects, ani-
mals within each cage should be randomised to diﬀer-
ent treatment groups. Alternatively, if the animals’
behaviour is too signiﬁcantly aﬀected by the stroke to
be housed with sham-operated or naı¨ve animals, the
same surgery may be performed on all animals in one
cage. This however has implications for the design and
analysis of the experiment, and in such cases, the
experimental unit would be the cage rather than the
individual animal.
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We recommend a pragmatic strategy for monitoring
group-housed animals (see section 6.1 ‘Monitoring of
animals’). If there is a suspicion or evidence that an
animal is behaving aggressively towards its cage mates,
then it may need to be removed until all other animals in
the cage have recovered adequately. It is plausible that a
sham-operated animal housed with impaired stroke ani-
mals may seek to change the hierarchy by asserting dom-
inance where previously it was submissive. Video
monitoring with an appropriate web cam can be used
to detect such behaviours during ‘lights out’ phase.
The issue of food and water post-stroke is dealt with in
the next section. Group-housing does prevent the meas-
urement of food and water intake (unless specialised
equipment is used) but the beneﬁts of group-housing
are thought to be more important.15 One way to ensure
equal access to food is to provide more food bowls than
animals in each cage. Scattering food pellets and several
packs of recovery gel on the cage ﬂoor also makes
access to food more equitable for group-housed animals.
8. After stroke, animals should be returned to the same
group of animals they were with before surgery as
soon as they are suﬃciently recovered.
9. The randomisation protocol should ensure that each
cage contains sham-operated and stroke animals, and/
or animals allocated to diﬀerent treatments.
2.5 Acclimatisation to post-stroke supplementary diet
Mice and rats are known to be neophobic and therefore
resistant to eating or drinking anything they do not
recognise.52,53 It is crucial that they are habituated to
any novel food or drink before the start of the experi-
ment and that surgery is not undertaken until animals
are acclimatised to it (see section 6.3 ‘Supplementary
ﬂuids and diet’ on supplementary ﬂuid and diet post-
stroke) to ensure that feeding and drinking activities
after the surgery are not reduced because of neophobia.
Feeding behaviour in rats and mice follows a diurnal
cycle, with the majority of food consumed at night or
during the dark phase.17,18 To respect the circadian
rhythm of the animals, new food should be put in the
cage before the active phase when animals will be feeding.
10. Animals should have access to their post-stroke diet
prior to surgery and surgery should not be under-
taken until they reliably consume the diet.
2.6 Food restriction pre-surgery
Withdrawal of food before general anaesthesia is gen-
erally not necessary in rodents as they lack the emetic
reﬂex54 and there is no risk that they will vomit during
surgery. Overnight fasting can actually be harmful in
rodents because of their high metabolic rate. It leads to
changes in pharmacokinetics, which may signiﬁcantly
impact the response to the drug under study and can
cause stress, aggressive behaviour and reduction in
body weight, temperature and plasma glucose levels.55
Even withdrawal of food for 6 h can lead to weight
loss and depletion of liver glycogen.56 Access to
water should never be restricted prior to general
anaesthesia.57
Food restriction can be justiﬁed for experiments spe-
ciﬁcally designed to study hyperglycaemia as, without
fasting or food restriction, blood glucose can be high
following the induction of anaesthesia58,59 and con-
found the outcome of the experiment. Rather than fast-
ing animals overnight, it is preferable to provide a
limited amount of food so that it runs out in the even-
ing and the animals have an empty stomach the next
morning. Prior to surgery, food may also be restricted
for other scientiﬁc reasons, including behavioural test-
ing that uses a food reward. Examples would include
skilled reaching in the staircase test60,61 and various
operant/lever-based tasks or touchscreen-based tasks.
However, in all these cases it is advised that animals
are pre-trained to a speciﬁed criterion and then
returned to food ad libitum for at least one dark
phase and an assessment made of their clinical condi-
tion (e.g. body weight and body condition score) prior
to surgery.
11. Rodents should not be routinely fasted before sur-
gery, unless there is a scientiﬁc reason; any restric-
tion should be reported speciﬁcally in publications.
12. After any food restriction for training purposes, suf-
ﬁcient time should be left to re-establish normal
feeding patterns before surgery.
2.7 Factors influencing host microbiota composition
The inﬂuence of microbiota composition and dysregu-
lation on a wide array of physiological and pathological
processes involved in health and disease is increasingly
recognised.62 In the context of CNS development and
function, the microbiota has been shown to exert
important inﬂuences through multiple mechanisms
including direct neural and humoural communication
and via regulation of the endocrine, metabolic and
immune systems, all of which themselves have import-
ant eﬀects on CNS homeostasis and pathology, includ-
ing stroke.63,64 A number of recent studies have
shown how experimental stroke in rodents modiﬁes
the gut microbiota composition, in part related to alter-
ations in gut permeability and motility.65–68
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In addition, several studies have shown that controlled
alterations to microbiota composition prior to stroke
(e.g. in germ-free conditions or induced by antibiotic
treatment) inﬂuence pathological and functional
stroke outcome measures including through immuno-
logical mechanisms).66,67,69 Many factors pertinent to
rodent stroke studies inﬂuence microbiota composition
including animal facility hygiene status, species and
strain, housing arrangements, diet and handling tech-
niques.64 It is therefore important to aim for consist-
ency in inter-animal and inter-study housing, feeding
and handling of animals (and cages including any asso-
ciated materials) such that potential inadvertent and
uncontrolled inﬂuences on microbiota are avoided. It
is also important to consider possible roles of micro-
biota alterations and downstream mechanisms (e.g.
immune perturbation) in studies where environmental
conditions are deliberately altered to test the eﬀects on
outcome (e.g. co-housing versus individual housing of
animals after stroke).
13. Consistency of inter-animal housing, feeding and
handling practices before and after stroke should
be ensured.
2.8 Specific requirements for aged animals and
those with co-morbidities
A major shortcoming of experimental stroke studies is
that they tend to ignore confounding factors, or co-
morbidities, which are known to impact upon stroke
outcome. Such confounding factors include increased
age, hypertension, diabetes, obesity, infection, inﬂamma-
tion and atherosclerosis.70,71 Age is considered to be
the most important independent risk factor for stroke
with stroke rates, in humans, doubling every decade
after the age of 55.72 In addition, age is a signiﬁcant
predictor of outcome, independent of stroke severity,
aetiology, thrombolysis, gender and other vascular risk
factors.73
Very few experimental studies exist in the literature
comparing outcomes after stroke in both middle-aged
and older animals and these tend to report inconsistent
results. Diﬀerent studies have shown that, in compari-
son to young males, aged males may have larger
infarcts, smaller infarcts or equivalent infarct size. In
spite of disagreements on the eﬀects of aging on infarct
volume, invariably signiﬁcantly higher mortality rates
and more severe neurological impairments are found in
older animals, consistent with clinical data.74–78 Such
detrimental eﬀects, in terms of function and animal
welfare, are a direct consequence of the ageing process
per se rather than the amount of ischemic damage gen-
erated. If the infarct volume is reduced in aged females
to that seen in young females by hormone supplemen-
tation, the poorer functional ability and increased mor-
tality remain in the aged females.74 Therefore, the
stroke model may need to be adjusted and more inten-
sive post-stroke care required in aged animal studies to
minimise morbidity and mortality. This also applies to
animal models expressing co-morbidities associated
with stroke such as hypertension, diabetes, hyperlipid-
aemia and metabolic disease. In addition, if aged ani-
mals, or those with other co-morbidities, are being
included in studies then this needs to be considered
during the experimental design stage as mortality
rates may diﬀer compared to studies using young,
healthy animals.
In aged animals it is important to monitor body
weight and general welfare of the animals whilst they
are being housed (i.e. even before they have undergone
stroke surgery). A programme of regular monitoring
should be in place to detect clinical signs that may indi-
cate a problem (see https://www.sharmuk.org/join-
sharm-community/welfare for further information). If
aged animals begin to experience weight loss this may
be caused by overgrown teeth which aﬀect their ability
to eat. It is considered good practice to provide aged
animals with chew blocks and to regularly check their
teeth. If overgrown teeth are identiﬁed they can be
trimmed, under brief general anaesthesia, using a
rotary dental disk cutter (for video see Wayman
et al.79). If overgrown teeth are identiﬁed then it is
likely that they will require fairly frequent treatment
(e.g. every two to four weeks) as overgrowth commonly
recurs probably due to misaligned upper and lower inci-
sors. If aged animals start to exhibit weight loss or
other changes in condition (e.g. piloerection) that is
not a result of recent surgery or overgrown teeth then
it is necessary to seek veterinary advice. If appropri-
ate intervention cannot restore the lost body weight
or body condition then it is recommended that ani-
mals are humanely killed (see section 6.1 ‘Monitoring
of animals’ on monitoring of animals post-stroke).
Magnetic resonance imaging (MRI) shows that eld-
erly Lister Hooded and Long Evans rats displaying
these symptoms often have pituitary tumours
(Lawrence Moon, personal communication).
Pituitary adenomas are also a common occurrence
in aged Sprague Dawley rats.80 If present, they are
inoperable and animals should be humanely killed.
Presence of co-incident disease or signs suggestive
of it, which is not the co-morbidity under test, will
probably alter scientiﬁc results. Use of such animals,
or their removal from the study should be reported in
publications.
14. Aged animals and those with co-morbidities should
receive extra monitoring.
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15. Teeth should be checked regularly, especially if the
animal is on soft food diet. Animals should be pro-
vided with chew sticks to grind teeth.
3 Anaesthesia and analgesia
3.1 General considerations
Knowledge of the general physiology of the animal and
its responsiveness to pharmacological agents, as well as
consideration of the duration of surgery, are essential
for selecting the most appropriate anaesthesia. Factors
such as age, strain, sex or body weight are known to
inﬂuence the pharmacokinetics and metabolism of
anaesthetic agents.57 Consideration should be given to
animal characteristics and particularly so with animals
harbouring co-morbidities or in very young or old ani-
mals. It may be prudent to optimise the anaesthetic
regimen in pilot studies where anaesthesia response
might be diﬃcult to predict. Many anaesthetic agents
require metabolism by the liver and/or renal excretion,
so recovery from anaesthesia may be compromised in
old or co-morbid animals. A notable exception is iso-
ﬂurane, which is 99% exhaled, and may be a good
choice for these animals. There are also signiﬁcant
strain diﬀerences in response to anaesthesia, particu-
larly with injectable agents,57,81,82 so caution is advised
when extrapolating doses between diﬀerent strains of
the same species.
Anaesthesia is required for induction of stroke with
almost all of the currently used models. Most studies
involve recovery of the animal following stroke induc-
tion, and so consideration will also need to be given to
post-operative care and analgesia. Anaesthesia may
need to be repeated following lesion induction, in
order to monitor the progression of ischaemic damage
and recovery, for example by use of functional MRI
(fMRI). Anaesthesia can have both direct and indirect
eﬀects on the extent of ischaemic damage induced, and
other factors in the perioperative period can also intro-
duce variability to the model. Many of these factors
were identiﬁed in the STAIR guidelines, with the rec-
ommendation that they should be controlled as part of
good study design.8 However a recent review of papers
reporting stroke induction in rodents indicates that the
majority of studies do not report use of measures to
minimise the eﬀects of anaesthesia, such as the use of
intubation and controlled ventilation, or maintenance
of adequate oxygenation.83
The choice of anaesthetic agent should reﬂect both
what is best for the welfare/physiology of the animal
and also the requirements of the experiment. Some of
the commonly used and recommended anaesthetics are
listed in Table 1 with some comments on their use;
however the choice of anaesthetic agent should be
based on a careful review of the relevant literature, par-
ticularly when using stroke models to assess potential
pharmacological interventions.
In experiments including sham-operated animals it is
imperative that they are exposed to exactly the same
duration of anaesthesia as MCA occlusion-operated
animals accounting for the pre-occlusion surgery,
occlusion and post-occlusion wound closure in order
to separate out stroke-speciﬁc eﬀects. Of note, previous
studies have documented the eﬀects of even brief peri-
ods of anaesthesia in comparison to non-anaesthetised
animals on stroke-related outcome measures.84
Guidelines on good research reporting practice suggest
that these details are important to allow accurate inter-
pretation and reproducibility of studies.14
3.2 Direct effects of anaesthetic agents
A range of anaesthetic agents are available for use in
rodents, and most, if not all, have the potential to inﬂu-
ence outcomes of stroke models, either directly or indir-
ectly. Both inhalational agents and injectable agents
can be used. Because of practical considerations, most
injectable anaesthetics are administered by the intraper-
itoneal route to small rodents, an approach that inev-
itably introduces additional variation because of the
relatively high incidence of extra-peritoneal administra-
tion of some of the injectate.85 Intravenous administra-
tion of anaesthetics is relatively straightforward in both
rats and mice, but maintenance of anaesthesia by con-
tinuous infusion is technically more diﬃcult in mice. In
rats, placement of a catheter percutaneously in the tail
vein enables total intravenous anaesthesia, with excel-
lent control of anaesthetic dose and depth of anaesthe-
sia.86,87 It is, however, often easier to use inhaled
anaesthetics, as the onset and recovery from anaesthe-
sia is rapid and the length and duration of anaesthesia
more controllable.88
Anaesthetic agents can have direct eﬀects on the size
of the ischaemic lesion and its progression, either
through neuroprotective activity, by eﬀects on neuro-
transmitters and receptor systems, or by induction of
hyperglycaemia. Modiﬁcation of neuroprotective path-
ways by general anaesthetics has been widely described.
These eﬀects should be taken into account in studies
testing eﬃcacy of a putative neuroprotective com-
pound. Nonetheless, since anaesthesia is a prerequisite
in animal stroke modelling it should be recognised that
any ‘protective’ eﬀects are only relative to an alterna-
tive agent. Isoﬂurane and sevoﬂurane improve neuro-
logical outcome compared with fentanyl in rat models
of ischaemia,89,90 possibly via a reduction of sympa-
thetic activity.90 Isoﬂurane was also shown to preserve
spatial memory in mice subjected to moderate hyp-
oxia91 and in vitro studies implicated mechanisms
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Table 1. Commonly used general anaesthetics.
Dose (mouse) Dose (rat) Comments
Gaseous
Isoflurane Allow animal to breathe 100% oxygen for
1 min before induction. Induce at 5%
isoflurane until anaesthetised, then reduce
quickly to maintenance level (usually 1.5–2%)
Isoflurane is more potent than
sevoflurane but the latter has
faster induction and recovery
(Fish et al., 2011)92Sevoflurane As above, with induction concentrations
of 8% and maintenance of 2.5–3.5%
Halothane As above, with induction concentrations of
4% and maintenance of 1.25–1.75%
No longer commercially available
in many countries
Ether Not recommended on health and safety
or humane grounds
Causes mucosal irritation and
forms explosive mixtures with
both air and oxygen
Injectable
Propofol 26 mg/kg i.v. as bolus to induce.
Maintain at 20–25 mg/kg/h infusion
10 mg/kg i.v. to induce.
Maintain at 20–25 mg/kg/h
infusion
Propofol i.v. gives consistent and
stable anaesthesia, but venous
access is more difficult in
mouse
Ketamine/xylazine 80–100 mg/kg ketamine þ
10 mg/kg xylazine i.p.
75–100 mg/kg ketamine þ
10 mg/kg xylazine i.p.
Causes hyperglycaemia and per-
ipheral vasoconstriction.
Anaesthesia can be partly
reversed with atipamezole s.c.
Ketamine/
medetomidine
75 mg/kg ketamine þ 1.0 mg/kg
medetomidine s.c. or i.p.
75 mg/kg ketamine þ
0.5 mg/kg
medetomidine s.c. or i.p.
Similar to ketamine/xylazine,
anaesthesia can be partly
reversed with atipamezole s.c.
Tribromoethanol
(Avertin)
Not recommended for recovery surgery Avertin can cause peritonitis
Medetomidine/
fentanyl/midazolam
0.5 mg/kg þ 50mg/kg
þ 5 mg/kg s.c.
150mg/kg þ 5mg/kg þ
2 mg/kg s.c.
Similar to ketamine/xylazine but
anaesthesia can be completely
reversed with atipamezole,
naloxone and flumazenil s.c.
Medetomidine (following
induction with 5%
isoflurane then
1% for maintenance)
– 50mg/kg bolus dose followed
15 min later by
100 mg/kg/hour s.c. infusion
This protocol can be used for
fMRI experiments, in which
isoflurane may cause a loss of
signal. The use of medetomi-
dine allows the concentration
of isoflurane to be reduced.
Bradycardia is a normal side
effect and the bolus injection
of medetomidine induces a
pronounced drop in blood
pressure. Medetomidine can
be reversed with atipamezole
100 mg/kg s.c.
Pentobarbital Not recommended Depth of anaesthesia cannot be
controlled safely unless
administered intravenously.
No longer available as a com-
mercial anaesthetic product in
many countries.
The data in this Table are from the text of section 3.1 ‘General considerations’ or from additional references.88,176,177
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involving intracellular Ca2þ regulation, several MAP
kinase pathways and modulation of apoptosis regula-
tors.93 On the other hand, isoﬂurane and several other
anaesthetic agents have also been shown to interfere
with neuroprotective mechanisms in response to hyp-
oxia, inhibiting erythropoietin upregulation in the
brains of mice.94 There is evidence that ketamine is
also neuroprotective.95,96 Although there is potential
for the anaesthetic to be a confounding factor, consist-
ent application of anaesthetic protocols and random-
isation will ensure that any neuroprotective eﬀect will
be controlled for. Even so, consideration of the magni-
tude of any systematic eﬀect is still important as a very
large eﬀect could mask a more modest but real eﬀect of
a drug.
Anaesthetic agents can also have a direct eﬀect on
CBF, a key variable in the development of ischaemic
lesions. The eﬀect is dependent both on the agent
selected and the dose administered. For example, of
the inhalant anaesthetics, halothane causes a greater
increase in CBF than isoﬂurane and sevoﬂurane.97,98
Injectable anaesthetics generally decrease CBF, with
the exception of ketamine.99 Anaesthesia also results
in changes in CBF indirectly because of eﬀects on the
respiratory system (see section 5 ‘Intraoperative care’).
Choice of anaesthetic can therefore directly bias the
results, but standardisation of methodology can
reduce variability due to direct anaesthetic agent eﬀects.
16. The anaesthetic should be chosen on the basis of
both welfare and scientiﬁc outcomes and should
take account of species, strain and health status of
the animals. Selection should involve the vet.
17. Sham-operated animals should receive exactly the
same anaesthesia regimen for the same duration as
the test group in order to control for eﬀects of the
anaesthetic on outcomes.
3.3 Local anaesthesia
Local/regional anaesthesia is recommended to control
pain induced by surgery. The use of a long lasting local
anaesthetic at the surgical site can reduce pain and
analgesic requirements. The anaesthetic should be
injected prior to surgery, to provide a regional block
into the area below the planned incision site. Once the
hypodermic needle is in place, pull back on the plunger
before injection to ensure that the needle has not
entered a blood vessel by accident, as intravenous
administration can be toxic.
Local anaesthetics act on Naþ channels to block
nerve transmission. However, there are increasing
reports of additional actions aﬀecting other processes
of relevance to stroke modelling, notably
immunomodulatory eﬀects.100 Inﬂammation and
immune processes are involved in multiple aspects of
stroke including underlying co-morbid disease and risk,
injury-induced inﬂammation, and the major complica-
tion of stroke, systemic infection via stroke-induced
immunosuppression.101 Local anaesthetics have potent
anti-inﬂammatory eﬀects (in some cases more so than
nonsteroidal anti-inﬂammatory drugs (NSAIDs))
including inhibition of cytokine production and leuko-
cyte traﬃcking, activation and phagocytic activity.100
They may also have anti-microbial properties.102 The
eﬀects are shared among the most commonly used
agents, with the notable exception of ropivacaine (S-
enantiomer speciﬁcally), which has relatively weak
anti-inﬂammatory activity.100,103,104 Avoidance of inad-
vertent intravenous injection should minimise compli-
cations arising from the above eﬀects. In addition,
ropivacaine may be a good choice in general (see also
desirable pharmacokinetic properties below) and par-
ticularly when analysis of immune inﬂuences on stroke
is the speciﬁc objective.
Lidocaine-containing creams (e.g. EMLA or LMX4)
can be used on the tail when i.v. catheters are inserted
for venous access (e.g. anaesthesia, ﬂuids) and also on
the ear bars when rodents are placed into stereotaxic
frames. LMX4 is a liposomal formulation that facili-
tates the extent of penetration into the skin in people,
and has a shorter onset of action (www.lmx4.co.uk).
Types of local anaesthetic agent and their pros and
cons are summarised in Table 2.
18. Local anaesthesia should be used prior to incision
during surgery, particularly if other types of anal-
gesia are not being provided, and with knowledge of
local anatomy to ensure that it is applied in the
appropriate area.
3.4 Analgesia
Since all rodent stroke models involve some form of
surgical intervention, post-operative pain can be antici-
pated. Pain may also occur as a result of the ischaemic
lesion. Pain is frequent after stroke (for example, head-
ache is reported by up to 38% of acute stroke vic-
tims)105 but it is not a predominant feature of human
experience, and would be treated if it occurred.
Uncontrolled pain does not make the animal model
more similar to the human condition under study. EU
Directive 63/2010 requires that analgesia is given unless
it interferes with the scientiﬁc outputs. Ethically, anal-
gesia should be administered to all animals in a study as
pain is a predicted outcome. This prevents pain or pain
relief becoming a confound in the experiment because
the analgesia is provided systematically as part of the
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experimental protocol, i.e. both test and control groups
receive it. Not controlling post-surgical pain in animal
models induces stress and additional uncontrolled vari-
ables in the experiment; animals experiencing pain will
not groom, eat, drink, or sleep normally.106–109 Some
analgesic agents have been shown to have measurable
eﬀects on infarct size and growth of the lesion (e.g.
buprenorphine110). However pain and the inﬂamma-
tory response to tissue damage, and the more general-
ised surgical stress response, also interact with lesion
induction. It may therefore be preferable to control
pain and reduce the uncontrolled eﬀects of tissue
trauma, to attempt to reduce variability within and
between treatment groups.
In the case of drug eﬃcacy studies, other factors,
such as competition of transport mechanisms, plasma
protein binding or metabolic pathways may inﬂuence
the selection of both analgesic and anaesthetic agents.
It should be possible to identify agents with minimal
potential interactions, and a decision to withhold anal-
gesia should only be based on strong, reproducible evi-
dence that the drug under study has a deﬁned
interaction with all available analgesic agents and that
the assessment of eﬃcacy would be compromised if
analgesics were administered. Equally, in mechanistic
studies, withholding analgesia should only be on the
basis of solid evidence that the process under investiga-
tion cannot be studied adequately in the presence of the
analgesic agent. In both cases, all potential means of
pain relief should be considered.
As with anaesthetic agents, the eﬀects of analgesic
agents that might interact with study objectives are
dose-dependent. It is therefore important that
appropriate doses of agents are administered for an
appropriate period (i.e. the doses needed to eﬀectively
control pain). This requires careful and accurate
assessment of the presence of pain and its severity
(see section 6.2 ‘Pain assessment in stroke models’).
Pain assessment also needs to be repeated at intervals
in order to determine the need for additional doses of
analgesic agents.
When selecting an analgesic agent, the speciﬁc
objectives of the experiment should be considered
alongside the mode of action of the analgesic so as to
minimise the impact of the broader eﬀects of analgesic
agents. For example, many analgesics, NSAIDs in par-
ticular, relieve pain primarily by inhibiting production
of inﬂammatory triggers of nociceptors, e.g. via
cyclooxygenase (COX) inhibition. Opioids, while
being strong analgesic agents, also have immunomodu-
latory properties with considerable evidence showing
immunosuppressive eﬀects.111–113 Buprenorphine has
a more favourable immune proﬁle relative to other opi-
oids (e.g. fentanyl, morphine) and thus may be a better
choice.113 Of note, a recent study showed that bupre-
norphine reduced pain scores without aﬀecting
neuroimmune responses in a mouse model of meningi-
tis.114 As noted above, inﬂammatory/immune processes
are involved in multiple aspects of stroke aetiology and
pathology (independently of pain pathways) and
stroke-induced infection, which worsens outcome, is
common in patients and observed in mice.115
Achieving pain relief without immunosuppression is
therefore desirable, particularly in studies directly
assessing immune function in stroke.
In terms of timing, analgesics should be adminis-
tered before noxious stimulation occurs. This may pre-
vent central sensitisation and also reduce the severity of
the responses to tissue injury, reduce nociceptor activa-
tion and prevent peripheral sensitisation. It is recom-
mended to integrate analgesic administration with the
anaesthetic protocol. The animal’s level of pain and
Table 2. Commonly used local anaesthetics.
Dose (mouse) Dose (rat) Comments
Injectable
Ropivacaine Infiltrate into surgical area at up to 2 mg/kg Ropivacaine less commonly used and weaker but
long lasting and less likely to be toxic from inad-
vertent intravenous administration than bupiva-
caine or lidocaine. Bupivacaine is long lasting,
lidocaine short acting. Ropivacaine has the weak-
est anti-inflammatory effects
Bupivacaine Infiltrate into surgical area at up to 2 mg/kg
Lidocaine
(lignocaine)
Infiltrate into surgical area at up to 10 mg/kg
Topical
EMLA Apply to clipped skin 20–30 min prior to
anaesthetic effect being required
2.5% lidocaine/2.5% prilocaine emulsion
LMX4 Topical application to clipped skin as for EMLA 4% lidocaine in liposomal formulation. More rapid
acting, longer lasting and less likely to enter the
systemic circulation than EMLA.
The data in this Table are from the text of section 3.3 ‘Local anaesthesia’ or from Laboratory Animal Anaesthesia.88
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need for pain relief should also be assessed objectively
(section 6.2 ‘Pain assessment in stroke models’) and
additional analgesic should be used if required. It can
be given to all animals at the same dose and timings
(including sham-operated and animals not exhibiting
pain behaviour) to avoid the eﬀects of the analgesic
agents becoming an additional uncontrolled variable
in the study. Alternatively if diﬀerent doses are used
in diﬀerent animals (to avoid pain being a confounder),
it needs to be speciﬁcally integrated into the design and
analysis of the experiment, and reported appropriately
in the publication. Animals should be assessed for pain
in between analgesic doses, to ensure that the regime is
eﬀective.
Analgesia should be given by the least stressful route
of administration, and voluntary consumption of indi-
vidual doses of analgesics in a palatable base has been
shown to be eﬀective (e.g. in ﬂavoured gelatine).116
However, medication of food or water has more vari-
able eﬀects, and it is important to ensure that the anal-
gesic is reliably consumed, in suﬃcient quantity.117 For
example, intake of analgesics in water may be unreli-
able for animals that are less mobile, or where the
taste of the water is altered by adding the drug.
Administration in food and water may be ineﬀective,
since food and water consumption are greatly inﬂu-
enced by diurnal rhythms, and animals may receive
ineﬀective doses during the light phase of their
photoperiod.117
Types of analgesics and their pros and cons are sum-
marised in Table 3. As with anaesthetic agents, consid-
erable variation between strains, ages and sexes in
analgesic doses is known to occur,118 so selection of
an eﬀective dose regiment will require use of pain
assessment.
19. Pain is a variable which needs to be controlled. Pain
relief must be used unless there are good scientiﬁc
reasons not to, supported by solid, reproducible
evidence.
20. The analgesic drug should be selected in consult-
ation with the vet, based on the objective of the
study, the speciﬁc stroke model and the type and
timing of outcome measures.
21. The animal should be assessed for level of pain post-
operatively, to ensure that the analgesic regime is
eﬀective and to minimise the risk of any unnecessary
medication or side eﬀects.
Table 3. Commonly used analgesics.
Mechanism Analgesic Dose (mouse) Dose (rat) Comments
NSAID Carprofen 10 mg/kg s.c.
(24 h duration)
2–5 mg/kg s.c.
(24 h duration)
Carprofen affords 24 h relief and can
be given by injection. COX-
blockers interfere with inflam-
mation processes. Can produce a
protective effect per se depend-
ing on dose and duration
Meloxicam 5–10 mg/kg p.o. or s.c. 0.5–1 mg/kg p.o. or s.c. Meloxicam affords 24 h relief and
can be given by injection or orally.
COX-blockers interfere with
inflammation processes
Ibuprofen and
aspirin
Not recommended Poor control of dosing when given
in drinking water, especially
aspirin which is poorly soluble
Opioid Buprenorphine 0.05–0.1 mg/kg s.c. 8 hourly.
Given before animal is
conscious because of
slow onset (40 min)
0.05–0.1 mg/kg s.c.
or p.o. 8–12 hourly.
0.5–1 mg/kg orally
Relative to other opioids least
affects inflammatory processes,
but inhibits glutamate release and
affects key stroke outcome
measures. Buprenorphine can be
given by injection or orally
Other Paracetamol 200 mg/kg once daily 50–150 mg/kg
twice a day
Can be given orally as a palatable
preparation. Poor control of
dosing when given in drinking
water if animals do not drink
post-operatively as is often the
case
The data in this Table are from the text of section 3.4 ‘Analgesia’ or from additional references.88
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22. All animals should either receive the same doses of
analgesics to avoid pain relief being a confounder, or
the experimental design and analysis should account
for animals receiving diﬀerent doses. This should be
reported explicitly in publications.
23. Analgesia should be given by the most reliable and
least stressful route. If there is doubt about oral con-
sumption, analgesics should be given parenterally.
4 Aseptic surgical techniques
Aseptic technique is essential for both scientiﬁc and
animal welfare reasons. Infection, as a result of poor
aseptic technique and contamination may lead to
inﬂammation, pain and delayed recovery, which may
well compromise the experimental outcome and cause
avoidable suﬀering.
While the goal of aseptic technique is to minimise the
risk of infection through surgical contamination, it is
also important to recognise that infection may be a
natural part of the response to stroke that is not due
to contaminating sources. Infection occurs in up to
one-third of stroke patients with bacterial pneumonia
the single most common cause.119 Recent studies have
also shown spontaneous bacterial pneumonia occurring
in rodent models of stroke.120–122 The mechanisms are
incompletely understood but stroke-induced suppres-
sion of some aspects of systemic immunity may be
important.115 Importantly, contamination from exter-
nal sources is not the source of the infection in these
cases but is most likely from increased invasiveness
and/or displacement of commensal microbes (e.g. aspir-
ation pneumonia). A recent study has also shown that
bacterial lung infection after experimental stroke can
result from increased stroke-induced gut permeability
and bacterial translocation.123 This is consistent with
human stroke studies where both respiratory and
gastrointestinal dwelling commensal bacteria have
been identiﬁed as causative agents in stroke-associated
pneumonia.124 Thus, if signs of infection are observed,
care should be taken in interpreting the cause/source.
Nonetheless, given that many animals that have under-
gone stroke induction, notably those with large MCA
territory infarcts, will be in at least a partially immuno-
compromised state, the need for aseptic technique is
further underscored. Extra consideration of the hand-
ling and housing of potentially immunocompromised
mice may also be necessary.
Prophylactic administration of antibiotics after
stroke in human patients did not reduce the incidence
of pneumonia or improve outcome compared to stand-
ard reactive treatment125,126 suggesting that routine
prophylactic administration of antibiotics in animal
stroke models may be similarly ineﬀective. Their use
is usually unnecessary if surgery is performed aseptic-
ally, and their presence may interfere with the experi-
ment (e.g. through alterations to microbiota
composition. See also section 2.7 ‘Factors inﬂuencing
host microbiota composition’). If antibiotics are used,
as with analgesics, all animals should be treated identi-
cally so that this factor is systematic and controlled for.
4.1 Planning for surgery
Prior planning and attention to detail is essential for all
surgical procedures and should encompass the prepar-
ation of instruments, consumables, facilities, the sur-
geon and the animal. Only the basic requirements are
listed below insofar as they apply to rodent stroke
models, and more detailed information is contained,
for example, in the Laboratory Animal Science
Association (LASA) Guiding Principles127 and in the
video tutorials from the Procedures With Care website
(www.procedureswithcare.org.uk).
It is important to ensure that the facilities are of an
appropriate standard for stroke surgery before begin-
ning any procedure on a live animal. The operating
theatre and preparation areas should have all unneces-
sary equipment and other items removed and should be
cleaned thoroughly between batches of animals. There
must be appropriate training and supervision in place
for new surgeons and a peri-operative care plan should
be agreed with the veterinary and animal care staﬀ
before surgery commences.
Ensuring adequate standards of both asepsis and
animal monitoring for a surgeon working on their own
is very challenging. The surgeon is already concentrating
on an involved manual procedure, making it diﬃcult to
monitor the animal’s vital signs in a meaningful way.
Achieving asepsis without a surgical assistant requires
a high degree of organisation, and can result in more
consumables being used and prolonged surgical time
(Paul Flecknell, personal communication). This can
increase the potential for adverse eﬀects in the animal,
and the variability in the experiment. Trained animal
care staﬀ can provide such assistance. Alternatively, in
small research groups with limited resources, colleagues
from other research groups can provide help during sur-
geries in exchange for similar help during their own
operations. In addition to managing the anaesthesia
and handling non-sterile equipment and consumables,
assistants can also prepare the next animal for surgery
and monitor animals that are recovering.
4.2 Preparation of surgical instruments and
consumables
All surgical instruments and/or consumables should be
checked well in advance of surgery with spares to hand
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in case of contamination or malfunction. This includes
checking that supplies of anaesthetic gases are suﬃ-
cient, particularly for long surgeries, and that any sub-
stances, solutions and medicines are not past their
expiry dates. If diluted formulations are needed these
should be prepared daily.
Instruments and surgical consumables such as
swabs, needles and suture materials should be appro-
priately packed and sterilised by autoclaving before use.
Autoclave tape can be used to indicate sterility. Ideally,
a new set of sterile instruments should be used for each
animal in order to avoid cross-contamination between
animals. If several animals are undergoing surgery
during a single session, then the choice is between
having the right number of sterile surgery and consum-
able kits ready beforehand, or sterilising instruments
after each use before starting to prepare a second
animal. Sterile disposable instruments can be a cost-
eﬀective alternative if autoclaving is not available
locally.
Bead sterilisers can be used during surgery to sterilise
the tips of instruments, or between animals during a
session of surgeries, but should not be regarded as an
alternative to autoclaving. In case of contamination,
the instruments/consumables should be replaced
between surgeries and sterile instruments should be pre-
pared for each session of surgeries. Other methods of
sterilisation, such as ethylene oxide or irradiation, can
be used for equipment which cannot be exposed to
steam, but alcohol or disinfectant are not recom-
mended, as these do not provide adequate sterilisation.
4.3 Preparation for the surgeon and assistants
‘Non-scrubbed’ surgical assistants must not touch ster-
ile instruments, drapes or consumables. The surgeon
and assistants should wear a head cover and a mask.
The mask should be applied before scrubbing, gowning
and gloving to cover all facial hair. Having taken oﬀ
any watches or jewellery, the surgeon should perform a
thorough scrub of hands and nails using a commercial
product designed for the purpose, such as Hibiscrub,
following the manufacturer’s instructions. With the
help of an assistant, the surgeon should put on a sterile,
long-sleeved operating gown. Sterile gloves should be
opened preserving sterility and worn over the cuﬀs of
the gown.
Throughout the procedure, the surgeon must be
careful to avoid touching non-sterile items such as the
table, the animal, experimental or anaesthetic equip-
ment, or the operating lights. If contamination
occurs, gloves should be replaced. Risk can be mini-
mised by wiping surfaces with disinfectant wipes prior
to surgery and covering with sterile drapes. Throughout
surgery, an assistant should be available to open the
outer packing of sterile items such as sutures or scalpel
blades, move the animal, and adjust the table and any
non-sterile equipment and to assist with monitoring the
depth of anaesthesia. If the surgeon needs to touch a
non-sterile surface for example to make ﬁne adjust-
ments to an operating microscope, the adjustable
knobs can be handled though a large sterile swab,
which is then discarded. Alternatively, it can be covered
with suitable sterile material, such as sterile foil or plas-
tic covering, before surgery starts.
4.4 Preparing the animal for surgery
Animals should be subject to a general observation (e.g.
general behaviour and condition of their skin and fur)
to ensure that no sign of illness or wounding by cage
mates is present before surgery.
The animal should be anaesthetised in a procedure
room which is separate from holding rooms which
house conscious animals. Following the induction of
anaesthesia, suﬃcient hair must be clipped from the
surgical site, using an electric clipper. This should be
done at a distance from the operating table or in an
adjoining room, to avoid contaminating the operating
area with hair, dander and associated sources of micro-
bial contamination. The shaved area should be large
enough to allow adequate skin preparation, prevent
hair ingress into the incision during surgery and after-
wards during wound healing. The size of the clipped
margin around the incision site should be the minimum
compatible with achieving the objectives outlined above.
The skin should be cleansed and then prepared with
a suitable topical solution (e.g. chlorhexidine, diluted in
alcohol or water, or povidone-iodine); alcohol alone is
not suitable as a skin disinfectant. These solutions
should not soak the whole animal, but should be
applied to the clipped skin in accordance with manu-
facturer’s instructions to reduce microbial contamin-
ation to minimal levels in the prepared area.
4.5 During surgery
The use of transparent disposable drapes over the animal
can aid anaesthetic monitoring. Sterile drapes should be
big enough to cover unprepared parts of the animal and
adjacent surfaces. Instruments should be placed on a
sterile drape or tray within the sterile ﬁeld; the drapes
should cover a suﬃcient area for the surgeon to lay out
and use instruments and suture materials without acci-
dentally contacting non-sterile items or surfaces.
4.6 Monitoring outcomes of surgery
Standards should be monitored to assess the surgeon’s
performance. Acceptable success rates for each type of
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surgery should be agreed on within the team, and sur-
geons who do not achieve it should either receive add-
itional training or refrain from operating on animals.
To that end, each surgeon should keep accurate records
of deaths during general anaesthesia and surgery,
wound breakdown, and requirement for intervention.
24. Aseptic surgical technique is essential.
25. Antibiotics should not be used prophylactically
unless there is a justiﬁed case.
26. The surgeon should work with an assistant.
27. Surgeons’ performance should be monitored and
reviewed.
5 Intraoperative care
Attention to care of the animal during surgery is as
important as the technical procedure itself in ensuring
good quality of outcome for both the animal and the
science. At the most basic level, support requirements
for anaesthetised rats and mice are warmth and oxygen.
5.1 Preparation for anaesthesia
The blink response will be lost under general anaesthe-
sia so it is important to protect the animals’ eyes.
Protective gel/drops (e.g. Viscotears, Lipolac, Lacri-
lube ointment or similar) will prevent drying of the
cornea during anaesthesia, and should be applied
immediately after clipping. If anaesthesia is prolonged,
re-application may be required after 30–40min.
5.2 During the surgery
5.2.1 Body and brain temperature. Temperature is particu-
larly important in stroke models, as hyperthermia (ele-
vated body temperature due to failed
thermoregulation) has been shown to be a determinant
of poor outcome following experimental stroke.128 In
fact, brain cooling, known as therapeutic hypothermia,
has been shown to be an eﬀective neuroprotective strat-
egy following ischaemic stroke.129
All anaesthetics result in hypothermia, because of
eﬀects on thermoregulation, by depression of metabolic
rate, and by peripheral vasodilation. Most experimental
stroke studies are performed in rodents and due to their
relatively small size and relatively higher surface area to
body weight ratio, they rapidly lose core temperature
unless measures are taken to prevent this. Small
rodents show a 1–2C fall in core temperature immedi-
ately following induction of general anaesthesia and
core temperature will continue to fall. Maintenance
of core body temperature should be viewed as a cen-
tral part of anaesthesia management to prevent
hypothermia. This should ideally be done through
a feedback-controlled system, which monitors the
core body temperature of the animal and adjusts the
temperature of the heating device to maintain
the desired body temperature. Heating mats and pads
may be less eﬀective when animals are placed in a
stereotaxic frame, since the area of the animal in con-
tact with the heat source can be greatly reduced. Use of
insulating material over the thorax and abdomen, and
tucking the tail under the animal’s trunk can help
reduce heat loss. Careful monitoring of body tempera-
ture is essential to ensure these measures are eﬀective. It
is common practice to monitor the eﬃcacy of warming
devices by recording rectal temperature; however this
does not always accurately reﬂect brain temperature in
man or animals.130,131
Special consideration is required for obese animals
as heat from heating pads does not dissipate as well
because fat is less well perfused. Problems can be
avoided by increasing the thickness of material between
the heating pad and the animal and by additional
monitoring of skin temperature (with an upper limit
of 41C).
28. During general anaesthesia and in the immediate
post-operative period, the animal’s body tempera-
ture should be maintained by insulation or supported
by a heating device, with a feedback heating system
that cuts out when normal body temperature is
reached.
29. Additional care and monitoring of body temperature
may be needed for obese animals.
5.2.2 Cardiorespiratory effects of anaesthesia. All anaes-
thetic regimens have depressant eﬀects on the respira-
tory system, resulting in an increase in arterial carbon
dioxide tensions (PaCO2). CBF shows a linear relation-
ship with PaCO2, increasing as PaCO2 increases, so long
as blood pressure remains within the normal physio-
logical range.132 These eﬀects can be controlled by endo-
tracheal intubation and ventilation of the animal.
Intubation and ventilation also enable easy manipula-
tion of the inspired oxygen concentration (FiO2),
another factor than can inﬂuence the ischaemic lesion.
In order to maintain tissue oxygenation, and cru-
cially, to avoid variation in the induction and progres-
sion of the cerebral infarct, oxygen can be delivered to
the animal via a nose cone, face mask or by oral intub-
ation, whether anaesthesia is by gaseous or injectable
agent. When induction of ischaemia can be achieved
rapidly (e.g. in less than 30min), and when the anaes-
thetic protocol does not result in signiﬁcant hypercap-
nia, the additional time needed for intubation may not
be warranted and a nose cone or face mask may
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represent the most straightforward approach. For pro-
longed anaesthetic protocols (over 30min), or protocols
when it is advisable to control arterial carbon dioxide
and/or oxygen tensions, then oral intubation with arti-
ﬁcial respiration should be considered as this will enable
physiological stability of the animal to be maintained. In
rats that are intubated and artiﬁcially ventilated, MCAO
surgery results in smaller infarct volumes and reduced
mortality compared to spontaneously breathing
animals.133
Endotracheal intubation is feasible in rats and a
wide range of techniques have been described.88
Although more challenging, it is also possible in mice.
Intubation can be carried out using an ‘over-the-needle’
catheter as an endotracheal tube and simple improvised
or specialist equipment.134,135 Following intubation, the
animal can be ventilated to maintain normocapnia
(normal arterial carbon dioxide pressure) and prevent
hypoxia. Species-speciﬁc ventilators should be used and
ventilators suitable for rats and mice are available from
a number of manufacturers. During prolonged anaes-
thetic protocols with artiﬁcial ventilation, problems
with increased secretions from lungs or mucus plugs
blocking intubation tubes can be avoided by prophy-
lactic administration of atropine (0.05mg/kg subcuta-
neous (s.c.) or intraperitonal (i.p.)) or glycopyrrolate
(0.5mg/kg intramuscular (i.m.)).88
Blood oxygenation can be monitored invasively by
blood gas analysis of arterial blood samples (partial
pressure of oxygen, PaO2 in mmHg) or non-invasively
by pulse oximetry (oxygen saturation of haemoglobin,
SaO2 in %). Normal levels of blood oxygenation for
rats and mice breathing air are 82–94mmHg88 and
95–97% SaO2. The normal range for carbon dioxide
in the blood is 35–45mmHg136 and this can be assessed
both by direct measures from arterial blood or by use of
capnography. Although blood gas analysis can be
undertaken using relatively small volumes of blood
(50–100 ml), this is too great a volume to allow repeated
sampling in rats, or even single samples in mice.
Capnography, even using specialised apparatus, does
not give as accurate a measure of arterial carbon diox-
ide in rodents in comparison to larger species, but it can
enable consistent levels to be maintained within and
between studies.88
Stroke models are also aﬀected by brain oxygen ten-
sion, both at the time of induction of the stroke, and
subsequently. Brain tissue oxygenation will be aﬀected
by a number of factors, including the use of oxygen as
the carrier gas for volatile anaesthetics, or as a means of
preventing hypoxia when injectable anaesthetics are
used. If medical air is used as a carrier gas, spontan-
eously breathing animals will become hypoxic, but nor-
moxia (and normocapnia) can be maintained by use of
intermittent positive pressure ventilation. Manipulating
the inspired oxygen content in spontaneously breathing
animals can enable more physiologically normal
oxygen content to be maintained, but these animals
will become hypercapnic. An FiO2 of 100% oxygen
will give PaO2 values in excess of 300mmHg when
the animal is artiﬁcially ventilated, and 200–
300mmHg in most spontaneously breathing animals.
An O2/N2O (e.g. 30:70) mix or 28–30% O2 will give
PaO2 values around 100mmHg with artiﬁcial ventila-
tion but in spontaneously breathing animals, hypoxia
may occur. If endotracheal intubation is not underta-
ken, then oxygen can be delivered to the animal via a
face mask or by nasal intubation, whether anaesthesia
is by gaseous or injectable agent. A face mask is the
most straightforward approach for brief surgical
protocols.
The eﬀects of anaesthetics on both respiration and
circulatory function are generally dose-dependent, so
minimising the dose of anaesthetic by use of adjuncts
such as local anaesthetics to provide additional anal-
gesia may be of value. Use of nitrous oxide to provide
additional anaesthetic and analgesic eﬀects is of limited
beneﬁt in small rodents, since minimum alveolar con-
centration (MAC) value (a measure of anaesthetic
potency) is high (indicating low potency) in both rats
and mice.137,138 However, 70% nitrous oxide can pro-
duce a 30% reduction in sevoﬂurane MAC in mice,138
so this agent may have some value as an anaesthetic
adjunct. Use of N2O mixtures with oxygen, to reduce
the FiO2 can be used, but N2O also has a wide range of
other eﬀects,139 so nitrogen or air mixtures with oxygen
are preferable.
5.2.3 Physiological monitoring during anaesthesia – General
considerations. Decisions as to the nature and extent of
monitoring animals during anaesthesia depend on the
level of interventions, equipment access and duration of
surgery and the scientiﬁc objectives of the study. The
potential beneﬁts of invasive monitoring need to be
balanced against the potential for causing additional
post-operative pain or discomfort (e.g. following arter-
ial cannulation). Monitoring basic physiological par-
ameters is essential for ensuring a controlled, stable
anaesthesia that is safe and eﬀective for the animal
and is likely to improve reproducibility of the study.
Basic requirements should include regular checking
for respiratory movement, normal pink colouration of
the extremities and adequate depth of anaesthesia (e.g.
assessed using the pedal withdrawal reﬂex), which
allows early identiﬁcation of problems than can be
quickly corrected. It is also important to keep a
record of these and surgical activities for each experi-
ment (e.g. start/end of procedure, signiﬁcant interven-
tions including drug administrations, any problems
encountered).
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Clinical monitoring can be challenging but specia-
lised monitoring equipment for small rodents is rela-
tively inexpensive, can record a rodent’s rapid heart
rate and be linked to a computer to record study
data. Non-invasive methods of monitoring such as
pulse oximetry should be used to ensure physiological
stability under anaesthesia. This technique measures
cardiorespiratory function via the tissue oxygen satur-
ation and heart rate with a sensor placed on the paw,
tail or tongue. As mentioned earlier, other non-invasive
methods of monitoring, such as capnography and sys-
tolic blood pressure (via tail cuﬀ plethysmography) are
technically more diﬃcult, due to the small size of the
animal. As mentioned above, it is often possible to use
capnography to standardise respiratory function within
and between studies, and this is strongly recommended
when inducing stroke, and subsequently in rodent
fMRI studies where stability of PaCO2 is also
important.
Mean arterial blood pressure, heart rate, blood gases
and pH can be monitored invasively with arterial (e.g.
femoral) cannulation. These enable accurate measure-
ment of the animal’s status but repeated blood sam-
pling for blood gas analysis will be limited by the
small size of rodents.
Individual animals may vary in precise values
for clinical parameters such as heart rate, so trends
in observations are more helpful in identifying sig-
niﬁcant deviations from normal. If the animal is
anaesthetised and intubated, variables such as PaO2,
PaCO2 and O2 can be controlled to be within the
physiological range by altering ventilator settings
(tidal volume and respiration rate) and percent
oxygen delivery. Small adjustments to the depth
of anaesthesia can help maintain a stable blood pres-
sure. Control of these variables therefore contributes
to improved reproducibility of stroke outcome
measures.
30. Monitoring of respiratory and cardiovascular par-
ameters is essential for animal safety and the repro-
ducibility of study methods.
31. Minimum parameters to monitor are depth of
anaesthesia, respiratory rate and temperature.
Surgical activities should also be recorded.
32. Pulse oximetry is recommended as SaO2 is a good
indicator of tissue oxygenation and heart rate is dif-
ﬁcult to monitor otherwise.
33. Invasive monitoring is useful for experiments carried
out under terminal general anaesthesia or for spe-
ciﬁc cases justiﬁed by the study needs.
34. Intubation and artiﬁcial respiration should be con-
sidered for experimental protocols involving induc-
tion of ischaemic lesions, particularly for those
lasting longer than 30min.
5.2.4 Fluid balance. During anaesthesia animals will
lose body ﬂuids, via a variety of routes. Some agents
(e.g. medetomidine and xylazine) cause a diuresis
and ﬂuid loss can be signiﬁcantly increased. During
the post-operative period, ﬂuid intake may be
reduced, especially in animals showing clinical eﬀects
of stroke.
Fluids should be administered to compensate for
these intraoperative and post-operative ﬂuid losses.
Fluids should be warmed to body temperature, and
be sterile and isotonic. Saline or Hartmann’s solution
is suitable and given at 1 ml/100 g bodyweight (i.v., s.c.
or i.p.) repeated every 1–2 h of anaesthesia.
35. Animals should be administered ﬂuids pre-emptively
to prevent dehydration during surgery.
6 Post-operative care
Following induction of cerebral ischaemia a number of
clinical signs will be present. Animals should be moni-
tored closely and assessment of clinical signs should
take into account the severity of the ischaemia induced
along with the health status of the animals pre-ischae-
mia as, for example, premorbid animals (e.g. hyperten-
sive, obese) can show accentuated adverse eﬀects
compared to normal young, healthy animals. Animals
should be monitored frequently (see below) to identify
any adverse eﬀects which would require further inter-
vention. Non-invasive home cage monitoring systems
can be used to record locomotor activity.140 Clinical
assessment sheets should be used to allow monitoring
of expected and unexpected adverse eﬀects.
To prevent hypothermia, temperature in the post-
operative room should be monitored. It should be
warm and local sources of heat such as heated cabinets
or heating pads should be used.
6.1 Monitoring of animals
Animals should be assessed at a time point considered
reasonable for recovery from the anaesthesia. This will
vary depending on the anaesthetic agent used, along
with the species and health status of the animals. It is
recommended that post-stroke animals are monitored
at least four times a day at regular well-spaced inter-
vals, during the ﬁrst 48 h. Beyond 48 h, animals should
be monitored at least once a day but the frequency of
monitoring should be increased if co-morbid animals
are used and if animals are showing any clinical signs
requiring intervention. Importantly, clinical assessment
sheets should be used to record such monitoring and be
kept with the animals. Monitoring should be done with
minimal handling but suﬃcient to allow adequate
18 Journal of Cerebral Blood Flow & Metabolism
welfare determination in order to identify those ani-
mals which (i) have reached a humane endpoint and
should be euthanised, (ii) are at highest risk of
not surviving and (iii) may require extra monitoring
and/or intervention such as extra ﬂuid supplementa-
tion. Clinical signs that may present following induc-
tion of cerebral ischaemia have been characterized as
green, amber or red, as detailed below (Table 4). The
guidelines apply to adult rodents from standard, com-
monly used strains and may need adjustment under
other circumstances (e.g. for aged, young or obese
animals).
GREEN – clinical signs similar to those seen in clin-
ical stroke are expected to be present after a focal
ischaemic insult as it results in brain injury and swel-
ling. For some studies where scientiﬁc endpoints can be
achieved by small infarcts, signs may be reduced in
severity or absent. It is anticipated that the majority
of animals will not display all of the clinical signs,
and any clinical signs should start to show improve-
ment by 48 h post-stroke.
AMBER – the presence of any of the signs in the
amber column below requires an increase in the fre-
quency of monitoring and appropriate intervention,
such as consulting the vet or implementing some of
the recommendations contained in this paper. If any
of the clinical signs exceed the limits stated, the
animal should automatically move to RED status.
RED – the presence of any of the signs in the red
column below requires immediate euthanasia of the
animal via an approved method of humane killing
(in the UK, Schedule 1 or other licensed method).
36. The experimental study plan should include
details of planned post-operative intervention
and assessment points. This should be devised
in consultation with veterinary and animal care
staﬀ.
37. Animals should be monitored frequently (at least
4 times a day at regular interval during the ﬁrst
48 h post-stroke) using a traﬃc light system
(see Table 4) and should be humanely killed if
they reach a pre-deﬁned humane endpoint (red
status).
38. Monitoring frequency must be increased if co-mor-
bid animals are used and if animals are showing
any clinical signs requiring intervention (amber
status).
39. Monitoring duration should be long enough to
ensure eating and drinking behaviours are
observed.
40. Clinical assessment sheets should be completed each
time animals are monitored – such sheets should
remain with animal cages to ensure record of obser-
vations and consistency of care.
6.2 Pain assessment in stroke models
We currently have very limited validated methods of
pain assessment in rodents. Clinical assessment of ani-
mals are usually non-speciﬁc for pain, however they
may be of value in allowing a structured evaluation
of the overall state of the animal. The introduction of
facial expression as a reasonably rapid and reprodu-
cible means of assessing pain in rodents oﬀers advan-
tages in ease of use, requiring minimal training of the
observer. These grimace scales are based on changes in
a number of ‘facial action units’, such as narrowing of
the eyes (orbital tightening) or changes in the position
and shape of the ears and whiskers. They have been
developed for both rats141,142 and mice143 and validated
for post-operative pain, e.g. in experimental myocardial
infarction and other surgical procedures.144–146
However, neither the grimace scales nor other pain
behaviours have been investigated and validated in
stroke models, and further research is necessary to
determine their sensitivity and speciﬁcity in these
models. The methods used to assess pain in stroke
models should be described explicitly in publications,
to allow a clearer picture to emerge.
6.3 Supplementary fluids and diet
To optimise welfare, physiological stability and help
minimise pain and discomfort, such as from needing
to reach for food and water, animals should be kept
adequately hydrated. Various methods are available
(e.g. subcutaneous ﬂuid injections, gel rehydration
packs, soft diet). Dietary supplementations, if not
part of the normal diet of the animal pre-operatively,
should be introduced before surgery in order for the
animals to overcome any neophobia.
Subcutaneous ﬂuids should be administered prophy-
lactically before stroke surgery to avoid dehydration.
Post-surgery, additional methods of rehydration
should be used routinely for severe stroke, but for less
severe models, an assessment of the need should be
made before giving additional ﬂuids. Animals should
be weighed frequently because the majority of weight
that is lost after surgery is usually due to loss of water:
this must be replaced. Signs such as sunken eyes or skin
tenting following a skin pinch indicate that dehydration
is already substantial; rehydration should be provided
well before animals display such signs.
In order to maintain hydration by subcutaneous
injection, local guidelines regarding volume limits
should be adhered to and advice sought from the rele-
vant person (e.g. animal welfare or veterinary staﬀ). An
example of a standard approach would be maintenance
ﬂuids of 2–4ml/kg/h (or 80ml/kg/day) using sterile and
isotonic ﬂuid (e.g. saline) which should be warmed to
Percie du Sert et al. 19
room temperature prior to use in order to avoid irri-
tation if ﬂuids are too cold. The route for rehydrating
an animal depends on the circumstances. In an awake
animal, the most eﬀective route of hydration is oral
and ﬂuid intake can also be maintained by providing
wet mash and/or recovery gel. The subcutaneous route
can be used if the animal is not swallowing well.
During anaesthesia, ﬂuids can be administered intra-
venously or, if there is no venous access, intraperito-
neally. For conscious animals, the intraperitoneal
route is painful and requires ﬁrm restraint, thus a
less stressful alternative is preferable. It is important
to monitor the eﬀectiveness of ﬂuid intake/administra-
tion by, for example, observing animals for evidence
of urination.
To encourage eating and provide ﬂuid, chow pellets
softened with water (‘mash’) can be provided in a plas-
tic weighing tray and additional dry pellets can be scat-
tered on the cage ﬂoor as animals may have diﬃculty
retrieving the pellets from the hopper and/or drinking
from water bottles after stroke. The soft food should be
replaced at least once daily for seven days. If animals
are group-housed after stroke as recommended, a suf-
ﬁcient number of soft chow trays and pellets should be
put in the cage to avoid any competition for food.
Providing wet food in the late afternoon ﬁts with nat-
ural feeding patterns of nocturnal animals, and may be
more eﬀective, as the food is fresh at this time.
If body weight drops by 10%, then food supplemen-
tation such as Complan, or baby food can be tried.
Table 4. Signs to monitor after experimental stroke surgery in rodent models.
r
GREEN AMBER RED
Timing
Anytime Sensorimotor deficits (e.g. forelimb 
weakness/hemiparesis, altered gait) 
Neglect of one side of the body, preference 
for one direction of movement 
Reduced food and water intake 
Abnormal behaviour upon handling – this may 
involve increased or decreased reaction to 
being handled compared to non-stroke 
animals 
Intermittent circling behaviou
Absence of urinea
Absence of faecesa
Surgical wound complication 
Reduced motility, beyond what would be 
expected based on the severity of the 
ischaemic insult 
Presence of barrel rolling 
Presence of tonic clonic seizures 
Continuous laboured respiration which is beyond 
what is considered normal for the age/weight of 
animal exposed to strokeb
First 24 h 
post-
stroke 
Lethargy and reduced motility with large 
strokes 
Animal not eating some normal chow or food 
supplement (e.g. wet mash) 
Animal not moving, unresponsive to  stimulation, or 
in a lateral recumbent position after the normal 
period of time expected for recovery from general 
anaesthesia, given the anaesthetic used, the duration 
of anaesthesia and the severity of the ischaemic insult.
First 48 h 
post-
stroke 
Weight lossc
Piloerection / staring coat 
Discharge from the eyes and nose 
Progressive weight loss exceeding 10% of the 
animal´s pre-stroke weight 
Audible respiratory noises (rasping, wheezing), 
usually intermittent and normally not 
associated with an increased respiratory effortb
Weight loss of 20% despite all efforts to supplement 
fluid and diet. A decision not to euthanise (e.g. if 
animal is eating well, drinking and able to move 
around and explore its environment) must be 
independently endorsed by the vet or animal welfare 
officer
First week 
post-
stroke 
Recovery of weight loss starting 4–5 days 
post-stroke 
Disruption to nest building activity during first 
week post-stroke – although this is strain 
dependent as some strains do not nest 
build176
Weight loss of up to 20% beyond 48 h post-
stroke (despite all efforts to supplement fluid 
and diet) but animal is eating well, drinking and 
able to move around and explore its 
environment. 
No recovery of weight towards pre-stroke 
level by 4 days post-stroke 
Intermittent abnormal motor activity, 
suggestive of seizure, during first 72 h only 
Piloerection beyond the first 48 h 
Reduced grooming beyond the first 48 h 
Secretions around the nose and eyes persisting 
beyond first 48 h 
No evidence of a return to near normal eating 
and drinking behaviour by day 4 post-stroke 
Weight loss exceeding 20% beyond 48 h post-stroke 
despite all efforts to supplement fluid and diet. A 
decision not to euthanise (e.g. if animal is eating well, 
drinking and able to move around and explore its 
environment) must be independently endorsed by the 
vet or animal welfare officer 
No recovery of weight towards pre-stroke level by 7 
days post-stroke. A decision not to euthanise (e.g. if 
the animal is eating well, drinking and exhibiting signs 
of normal behaviour) must be independently 
endorsed by the vet or animal welfare officer 
Intermittent abnormal motor activity, suggestive of 
seizure, persisting beyond first 72 h 
Intermittent abnormal and laboured breathing (e.g. 
rasping) observed for two consecutive observations, 
or persisting beyond the first 48 hb
aThese would typically be observed in singly housed animals to assess if the animal is eating and drinking sufficiently. However, group-housing has been
shown to aid recovery (see section 2.4 ‘Social housing post-stroke’). In group-housed animals, observing eating/drinking habits, monitoring body weight
and whether the animals defecate/urinate during handling can be used to assess whether each animal is eating and drinking sufficiently.
bAbnormal breathing which is beyond what is considered normal for the age/weight and characteristics of animal exposed to stroke. For example,
obese animals may exhibit noisier rasping respiration than non-obese animals.180 Intermittent wheezing (amber sign) can be seen in the first 24 h after
MCAO and is normally associated with intubation and/or long or repeated anaesthesia, most likely due to accumulation of respiratory secretions and/
or minor laryngeal trauma. It should resolve within 24–36 h. Respiratory distress (red sign) may be a result of pulmonary oedema associated with the
MCAO181,182 or severe laryngeal trauma at the time of intubation.
cWeight loss after stroke is common, both in humans and in rodent models, and can be explained principally by dehydration, impaired feeding, inactivity
and paralysis. However, other factors such as neuroendocrine sympathetic activation, fever and inflammation also contribute to metabolic imbalance
and an increased catabolic drive leads to tissue wasting of both fat and muscle, depleting energy stores and leading to functional decline. Rodent models
typically demonstrate a dramatic weight loss after stroke surgery, which normally starts recovering after 4–5 days. The amount of weight lost during
that period is tightly correlated with the size of the infarct179 (see Figure 1).
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Also hand feeding animals should be considered to
encourage weight gain after stroke surgery. The sugar
content of any planned supplement should be con-
sidered as high sugar foods might increase blood glu-
cose levels and exacerbate acute ischaemic damage.
Post-operatively, swallowing may be impaired by
stroke so liqueﬁed foods that might be inhaled should
be avoided.
41. Dehydration should be assessed frequently and trea-
ted post-operatively until the animal is seen to be
drinking normally.
42. Additional hydration should be provided at least for
the ﬁrst two days post-surgery.
43. Animals should be provided with an appropriate
post-surgical diet (e.g. wet mash). Softened food
and loose pellets on the cage ﬂoor should be supplied
for at least seven days post-stroke.
7 Refinement for specific models
7.1 Intraluminal filament model
7.1.1 Entry point of intraluminal filament when using the intra-
luminal filament model. In rats the ﬁlament can be intro-
duced through an opening in the CCA, internal carotid
(ICA) or the external carotid artery (ECA). The ori-
ginal approach via the ECA results in the ECA being
cauterised and therefore disrupts the blood supply to the
ECA territory, including facial musculature. This leads
to signiﬁcant additional weight loss, drinking impair-
ments and confounds in behavioural measures.
Avoiding permanent ligation or cauterisation of the
ECA is a reﬁnement; it prevents damage to the muscles
of mastication and reduces weight loss, drinking impair-
ments and reduces confounding side eﬀects of surgery on
behavioural outcomes.148–150 This can be achieved by
introducing the ﬁlament via the CCA with either per-
manent ligation of the artery or careful sealing of the
incision on ﬁlament removal148,149 which results in com-
parable outcomes.148 However, as variable stenosis of
the CCA was reported when sealing an incision in the
CCA,149 tieing oﬀ the CCA is recommended to reduce
variation. The ﬁlament may also be introduced via the
ICA.150 The use of these approaches does not alter the
size or variability in infarct volume compared to enter-
ing via the ECA in rats and therefore are preferable par-
ticularly if behaviour is an outcome measure.
Filament insertion into the ECA or CCA is pos-
sible in mice.151 However, care should be taken as
vascular anatomy is variable between mouse strains,
with incomplete circle of Willis reported in some
strains.152–154
However, if the CCA or ICA is tied oﬀ, the ipsilat-
eral CBF may recover to approximately 80% of base-
line.151 This approach may thus not be appropriate for
a study looking at blood ﬂow. However, this is not
pathological – increased infarct volumes, or increased
gliosis in comparison to the ECA model have not been
reported. No pathology has been reported either in
sham animals which have one carotid artery tied oﬀ.148
7.1.2 Right versus left MCA occlusion. The side of occlusion
can be altered and is often a matter of the surgeon’s
preference. Left-handed surgeons tend to ﬁnd that
occluding the right MCA is easier and vice versa.
However, it should be noted that the side of occlusion
can aﬀect experimental outcomes.155 In addition, in
Figure 1. (a) Mean body weight after 60 min of middle cerebral artery occlusion (MCAO) in the BL6 mouse strain (n¼ 10). Note the
dramatic drop and slow recovery of body weight, whereas nonmanipulated control mice gain 1 to 2 g per week. (b) Correlation of
infarct size with loss in body weight 72 h after 60 min of MCAO. Note the very tight correlation between infarct size and loss in body
weight. 95% CIs for the population mean (regression). Reproduced with permission from Dirnagl.183
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some cases, experimenters assess paw dominance before
surgery and lesion the dominant hemisphere in each
animal to give more robust behavioural deﬁcits.
7.1.3 Coagulating the occipital artery, superficial temporal
artery branches and pterygopalatine artery. This helps to
control blood loss and prevent collateral perfusion or
retrograde blood ﬂow. However, it alters blood ﬂow to
structures external to the MCA territory, which could
impact on recovery of the animal and functional out-
come measures.
7.1.4 Waking the animal during the occlusion period. Waking
the animal up during the occlusion period reduces the
total exposure to anaesthetic agents. Some groups anec-
dotally report better recovery when doing this.
Behavioural signs, such as circling, twisting when held
brieﬂy by the tail, and lack of response to whisker
stimulation on the contralateral side can be used
during this period for rapid assessment to conﬁrm
stroke. On the other hand, by keeping the animal on
the operating table anesthetized for the duration of sur-
gery, temperature can be more tightly regulated and
other physiological parameters including CBF can be
directly assessed during the ischaemic insult.
7.1.5 Refinement to reduce mortality in severe strokes. A
reﬁnement for intraluminal ﬁlament-induced transient
MCA occlusion in spontaneously hypertensive stroke-
prone rats (SHRSP) has been reported, which reduces
mortality and post-stroke associated weight loss.156
SHRSP rats exhibit many of the co-morbidities asso-
ciated with stroke clinically including hypertension,
altered glucose handling and elevated inﬂammatory sig-
nalling. The reﬁnement involves an additional general
anaesthetic, a cranial burr hole and durotomy six days
prior to transient MCA occlusion and was identiﬁed by
chance in an earlier study which required a general
anaesthetic and stereotaxic injection of a substance
one week prior to stroke.
Although recommended for intraluminal ﬁlament
transient MCA occlusion in SHRSP, this reﬁnement
would be worth applying in any of the closed skull
models where mortality is an issue.
7.1.6 Choice of filament. Several suture materials and
methods for blunting or coating ﬁlament tips have
been used in ﬁlament MCA occlusion studies.157–159
The most appropriate will depend on a number of fac-
tors including animal species, strain, weight, surgical
approach and vascular architecture. Key consider-
ations include the ﬂex and diameter of the main ﬁla-
ment and the diameter and length of the tip
coating.160 Flex and diameter of the main ﬁlament
are important to enable passage along the kinks in
the internal carotid as it passes through the skull.
More ﬂex is also likely to minimise the risk of punc-
turing the vessel at the base of the brain and causing
a bleed as the force of pushing is not transmitted as
strongly. Tip diameter and length will inﬂuence the
occlusion success but may also aﬀect the distribution
of damage, instance of skull base subarachnoid
haemorrhage and associated morbidity.159–162 While
a thicker and longer coating could ensure more con-
sistent occlusion, it may also occlude other deep ves-
sels branching directly from the circle of Willis to
subcortical structures, although this will depend on
speciﬁc species and strain cerebrovascular architec-
ture. The intraluminal ﬁlament occlusion model
results in an occlusion duration-dependent increase
in severity of cerebral hypoperfusion within, and sur-
rounding the MCA territory.154 Beyond the MCA
territory, regions such as the thalamus, hypothalamus
and hippocampus may be aﬀected as a consequence
of the ﬁlament occluding more proximal arteries that
arise from the ICA (e.g. anterior choroidal and hypo-
thalamic artery163) or because animals have a heredi-
tary incomplete circle of Willis. It is thought that
damage to such areas as the hypothalamus comprom-
ises the stress and inﬂammatory responses and gener-
ates a hyperthermic response persisting following
recovery.164 In general, the smallest diameter and
shortest coating that produces consistent MCA terri-
tory injury should be used.
Until recently, most labs made their own ﬁlaments
and considerable diﬀerences across labs were evident.
However pre-made ﬁlaments in various sizes to suit dif-
ferent applications are now available from commercial
sources (e.g. Doccol) and increasingly employed.
Consistency aﬀorded by commercial manufacture may
contribute to improvements in reproducibility.
7.2 Embolic stroke
The intraluminal approach is also used to induce
embolic stroke, the ﬁlament being replaced by a ﬁne
cannula, loaded with a pre-formed blood clot. The
point of entry for the cannula is either the CCA or
ECA as for the ﬁlament model and the tip advanced
towards the origin of the MCA to release the clot.
Although this is the most clinically relevant model, it
is also one of the most diﬃcult to achieve reproducibil-
ity in outcome measures even between surgeons in a
single laboratory, and induces signiﬁcant mortality
(e.g. >30%).165 Stroke severity can be controlled by
altering the composition and length of clot injected
and the rate at which the clot is injected. Therefore, it
would not be the model of choice to use for early stu-
dies of new stroke therapeutics, unless they were
thrombolytics. However, if a therapy demonstrates
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eﬃcacy with the non-embolic stroke models, it would
be important to test it in combination with rtPA in the
embolic model to conﬁrm no adverse interactions with
the current licenced therapy and to investigate any syn-
ergistic or additive eﬀects.
7.3 Photothrombosis
Photothrombosis provides a more controllable model
of blood clot-induced ischaemia mediated by generat-
ing a thrombus within cortical pial vessels. Cortical
ischaemia has been induced by photothrombosis in
various species including rats and mice. The procedure
involves surgical anaesthesia, incision of the skin at the
midline overlying the skull and then placement of a
light source perpendicular to the location of infarct
that is desired. In rats, skull thinning using a drill is
done by some laboratories and not by others. A
photosensitive dye, Rose Bengal, is injected by one
of various routes: the intraperitoneal and intravenous
routes are the most commonly used. Immediately
thereafter, or after a delay, a light beam is shone
through the thinned skull for a speciﬁed period. This
initiates formation of a thrombus and local ischaemia
(see Alaverdashvili et al.166). Various light sources may
be used. Some groups use lasers which emit at a suit-
able wavelength for Rose Bengal. Others shine light
from a wide-spectrum cold-light source via a ﬁbre
optic light source: the Schott KL 1500 LCD is very
commonly used.
Care should be taken not to heat the skull and brain
even when using ‘cold-light’ sources. Many cold-light
devices use 150 W halogen lamps that are hot and can
burn (due to emission of infrared and ultraviolet wave-
lengths). This is particularly true when illumination is
used at the highest settings (e.g. when using an intensity
of 3300K colour temperature and setting ‘6E’ on the
Schott KL 1500 LCD). Many groups now use illumin-
ation of 3000K in rats to reduce mortality (Nicolas
Lindau and Lukas Bachmann, personal communica-
tion) whilst another uses 3200K using the Schott KL
200 light source (Antje Schmidt, personal communica-
tion). Finally, for rats, another group uses 3200K plus
a lower setting (5C, Schott KL 1500 LCD) plus a green
insert ﬁlter to exclude infrared and ultraviolet wave-
lengths but to pass wavelengths of light that stimulate
Rose Bengal (peak 560 nm) (Geralda van Tilborg,
personal communication).167 For mice, some place the
tip of the ﬁbre optic directly on the skull168 and others
lift it 2mm above the skull (Geralda van Tilborg, per-
sonal communication). When using a cold-light source,
we recommend that the target of the ﬁbre optic is tested
for temperature. Initially after turning on, the target
may be cold but with time, intense illumination can
cause burning.
Mannitol may be used to attempt to reduce swelling
after photothrombosis in adult rats169 but anecdotally
this is not eﬀective in mice (Nicolas Lindau, Lukas
Bachmann, personal communication). Mice with low
body weights (and little body fat) (e.g. <20 g) appear
to survive cortical ischemia by photothrombosis less
well than mice with higher body weights (and more
body fat). It may be useful to provide supplementary
warmth during surgery, and post-operatively overnight
(e.g. 25C) and for several days thereafter (Michelle
Porritt, personal communication).
7.4 Thrombin injection
A localised thromboembolic stroke can also be
induced by the in situ injection of thrombin within
the lumen of a distal branch of the MCA.170 The
resulting thrombus produces a very reproducible cor-
tical infarct in mice, although rapid spontaneous
thrombolysis can be a source of variability. The
blood clot can be successfully lysed by rtPA making
this model suitable for the study of new thrombolytic
drugs or drugs used in combination with thrombo-
lytics. However, although the location and extent of
the infarct is very reproducible, the infarct per se, is
small and little or no neurological deﬁcit can be
detected. Therefore this model would be less useful
to study functional outcome.
7.5 Endothelin-1
Endothelin-1 is a potent and long lasting vasocon-
strictor peptide and therefore an ideal agent for indu-
cing small, focal ischaemic lesions. Using a stereotaxic
frame and co-ordinates, focal ischaemic lesions are
induced by stereotaxic microinjection of endothelin-1
into speciﬁc neuroanatomical sites (e.g. white matter
tracts such as the internal capsule) in adult or elderly
rats.171,172 In rare cases, animals can exhibit ‘barrel roll-
ing’ or seizures after injection of endothelin-1. This may
happen if endothelin-1 accidentally enters the ven-
tricles. In our experience the prognosis is not good
and we recommend prompt, humane killing of any ani-
mals that display barrel rolling behaviour (see section
6.1 ‘Monitoring of animals’). Accordingly we recom-
mend that endothelin-1 is injected into the brain via a
route that does not impinge on the ventricles; oblique
angles may be used to target deeper structures such as
the internal capsule.173
7.6 Permanent MCAO by electrocoagulation in
rat or mouse
Permanent occlusion of the main trunk of the MCA or
its distal branches can be achieved by
Percie du Sert et al. 23
electrocoagulation. In this experimental model, the
MCA is exposed by a craniotomy and opening of the
dura mater. Using ﬁne diathermy forceps, a current is
passed through the artery which induces blood clotting,
destruction of the artery walls and ischaemia distal to
the electrocoagulation site. Sectioning the occluded
part of the artery with microscissors, once electrocoa-
gulation is complete, provides conﬁrmation of complete
occlusion. The severity and location of the ischaemic
insult can be controlled by the length and location of
the MCA segment to be electrocoagulated. Large
infarcts incorporating subcortical and cortical tissue
are induced by occluding the artery from a point prox-
imal to the lenticulostriate branches to the point where
the MCA crosses the inferior cerebral vein.174
Alternatively, occluding a distal segment of the MCA,
immediately above and below the point where it crosses
the inferior cerebral vein, produces a reproducible cor-
tical lesion that incorporates the forelimb and hindlimb
regions of the motor cortex, allows sensitive neuro-
logical scoring and motor deﬁcits to be detected and
is characterised by good recovery and low mortality.
Shorter, distal occlusion of the artery distal to the infer-
ior cerebral vein leads to small, variable (or no) infarcts
conﬁned to the cortex.175 To generate more consistent
infarcts, permanent distal MCA occlusion can be com-
bined with tandem CCA occlusion in rats.79 Surgeons
should start with a short CCA occlusion time (e.g.
30min) to see whether adequate lesion volumes
(and/or required behavioural deﬁcits) are obtained
and only then increase CCA occlusion if necessary.
Anecdotally, higher mortality is found in elderly male
rather than elderly female rats with equivalent
occlusion times so shorter occlusion times may be
required for elderly males. Choice of the side of occlu-
sion (left or right MCA) is subject to similar consider-
ations to the intraluminal ﬁlament model. Another
consideration is the diﬀerence in skull thickness
between rodent species: mice have thinner skulls than
rats, allowing relatively easier craniotomy and localiza-
tion of the MCA.
In summary, the advantages of electrocoagulation
models are better control over the completeness of
MCAO, variability and location of ischaemic lesions
(e.g. cortical, or cortical plus sub-cortical involvement)
and low mortality. However, variation in the MCA
anatomy may inﬂuence the size of the infarct, surgery
is more invasive and challenging than for intraluminal
ﬁlament MCAO, which can extend the time under gen-
eral anaesthesia and there is no potential for reperfu-
sion through the occluded artery.
8 Concluding remarks
Stroke models can be severe but here we present small
incremental changes, which can improve the welfare of
the animals used. The recommendations presented in
this manuscript are recapitulated in a summary docu-
ment (see supplementary information) which can be
printed oﬀ as an easy reference sheet for researchers,
animal welfare staﬀ or editors. Table 5 also provides a
high level summary of all the recommendations.
In making these recommendations we have to
acknowledge certain weaknesses in our approach. We
have referred to the literature wherever possible, and
where there are gaps in published information or, as is
Table 5. Summary of recommendations.
Basic requirements before
stroke surgery
Rodents should be group housed in appropriate housing conditions and acclimatised to their
environment, cage mates, diet and monitoring procedures. Cages should include animals
allocated to different groups (recommendations 1–15)
Anaesthesia and analgesia The anaesthetic and analgesic protocols should be chosen on the basis of both welfare and
scientific outcomes, and the effectiveness of pain relief should be assessed. Care should be
taken to choose an anaesthetic and analgesic which are compatible with the outcomes of
the experiment and so that pain is not a confound (recommendations 16–23)
Intraoperative care Using aseptic techniques is essential and can be achieved more readily if the surgeon works
with an assistant. Core temperature, cardiovascular and respiratory parameters, and
depth of anaesthesia should be monitored and maintained. Intubation and artificial
respiration should be considered for experimental protocols involving induction of
ischaemic lesions, particularly for those lasting longer than 30 min (recommendations
24–35).
Post-operative care Post-operative intervention, assessment points and humane endpoints should be agreed in
advance with veterinary and animal care staff. Animals should be monitored frequently
using a traffic light system and clinical assessment sheets; monitoring frequency should be
adapted to the condition of individual animals and animals reaching a pre-defined humane
endpoint should be promptly and humanely killed. Animals should be kept hydrated and
provided with an appropriate post-surgical diet (recommendations 36–43).
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quite common, the evidence is conﬂicting, we have relied
on the expert opinion and experience of the authors and
we present here a consensus of their views. In addition,
we recognise that every study has to take into account its
individual constraints and objectives and therefore there
is no single recipe for the best approach.
With this in mind, we emphasise the real importance
of careful planning at every stage of the process, includ-
ing transport, housing, acclimatisation (including novel
diet), anaesthesia, analgesia, post-operative care, use of
a scientiﬁc scoring system to assess wellbeing, and def-
inition of intervention points and humane endpoints.
Awareness of external developments in reﬁnement
and internal consultation with animal care staﬀ and
vets before surgery are essential.
The evidence base is currently lacking for some aspects
of stroke modelling in rodents. Particularly, more
research is needed to validate methods of assessing pain
in stroke animals, to investigate whether and how anal-
gesic agents interact with stroke mechanisms, and assess
the impact of environmental enrichment on stroke out-
comes.We emphasise the need for comprehensive report-
ing and disclosure of potential confounding factors in
publications so that peers can interpret results, put them
in context and beneﬁt from the experiences of others.14
Training for researchers, students and animal tech-
nicians is of course vital and lack of training and/or
resources should not be used as a reason to use lower,
though legally acceptable, standards.
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